The CEA Registry Blog

By CEA Registry Team on 5/6/2015 12:03 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Bhanegaonkar AJ, Horodniceanu EG, Abdul Latiff AH, et. al. Economic value of atopic dermatitis prevention via infant formula use in high-risk Malaysian infants. Asia Pac Allergy. 2015 Apr;5(2):84-97. Epub 2015 Apr 29. PubMed PMID: 25938073.

2: Miquel-Cases A, Steuten LM, Retèl VP, et. al. Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy. Breast. 2015 Apr 28. [Epub ahead of print] PubMed PMID: 25937263.

3: Brown GC, Brown MM, Turpcu A, et. al. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema. Ophthalmology. 2015 Apr 29. [Epub ahead of print] PubMed PMID: 25935787.

4: Brusco NK, Watts JJ, Shields N, et. al. Is cost effectiveness sustained after weekend inpatient rehabilitation? 12 month follow up from a randomized controlled trial. BMC Health Serv Res. 2015 Apr 18;15(1):165. [Epub ahead of print] PubMed PMID: 25927870.

5: Goldhaber-Fiebert JD, Brandeau ML. Evaluating Cost-effectiveness of Interventions That Affect Fertility and Childbearing: How Health Effects Are Measured Matters. Med Decis Making. 2015 Apr 29. [Epub ahead of print] PubMed PMID: 25926281.

6: Burn E, Marshall AL, Miller YD, et. al. The cost-effectiveness of the MobileMums intervention to increase physical activity among mothers with young children: a Markov model informed by a randomised controlled trial. BMJ Open. 2015 Apr 29;5(4):e007226. PubMed PMID: 25926145.

7: Li Y, Bare LA, Bender RA, et. al. Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma. Mol Diagn Ther. 2015 Apr 30. [Epub ahead of print] PubMed PMID: 25926090.

8: Botteman M, Detzel P. Cost-effectiveness of partially hydrolyzed whey protein formula in the primary prevention of atopic dermatitis in high-risk urban infants in southeast Asia. Ann Nutr Metab. 2015;66 Suppl 1:26-32. Epub 2015 Apr 24. PubMed PMID: 25925338.

9: Lee JY, Kim Y, Lee TJ, et. al. Cost-effectiveness of para-aortic lymphadenectomy before chemoradiotherapy in locally advanced cervical cancer. J Gynecol Oncol. 2015 Apr 17. [Epub ahead of print] PubMed PMID: 25925292.

10: Zhang P, Yang Y, Wen F, et. al. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2015 Apr 22. [Epub ahead of print] PubMed PMID: 25919775.

11: Nghiem VT, Davies KR, Beck JR, et. al. Economic evaluation of DNA ploidy analysis vs liquid-based cytology for cervical screening. Br J Cancer. 2015 Apr 28. [Epub ahead of print] PubMed PMID: 25919612.

12: Imaz-Iglesia I, Miguel LG, Ayala-Morillas LE, et. al. Economic evaluation of Chagas disease screening in Spain. Acta Trop. 2015 Apr 25. [Epub ahead of print] PubMed PMID: 25917718.

13: Fox GJ, Oxlade O, Menzies D. Fluoroquinolone Therapy for the Prevention of Multi-drug Resistant Tuberculosis in Contacts: a Cost-effectiveness Analysis. Am J Respir Crit Care Med. 2015 Apr 27. [Epub ahead of print] PubMed PMID: 25915791.

14: Snowsill T, Huxley N, Hoyle M, et. al. A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. BMC Cancer. 2015 Apr 25;15(1):313. [Epub ahead of print] PubMed PMID: 25910169.

15: Gustafson DH Sr, McTavish F, Gustafson DH Jr, et. al. The effect of an information and communication technology (ICT) on older adults' quality of life: study protocol for a randomized control trial. Trials. 2015 Apr 25;16(1):191. PubMed PMID: 25909465.

16: Fleeman N, Bagust A, Beale S, et. al. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. Pharmacoeconomics. 2015 Apr 24. [Epub ahead of print] PubMed PMID: 25906420.

17: Meier G, Gregg M, Poulsen Nautrup B. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the United Kingdom. J Med Econ. 2015 Apr 23:1-40. [Epub ahead of print] PubMed PMID: 25903831.

18: Westerhout K, Treur M, Mehnert A, et. al. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service. J Med Econ. 2015 Apr 23:1-19. [Epub ahead of print] PubMed PMID: 25903830.

19: Troyer JL, Jones AE, Shapiro NI, et. al. Cost-effectiveness of Quantitative Pretest Probability Intended to Reduce Unnecessary Medical Radiation Exposure in Emergency Department Patients With Chest Pain and Dyspnea. Acad Emerg Med. 2015 Apr 21. [Epub ahead of print] PubMed PMID: 25899550.

20: Groot-Jensen S, Kiessling A, Zethraeus N, et. al. Cost-effectiveness of case-based training for primary care physicians in evidence-based medicine of patients with coronary heart disease. Eur J Prev Cardiol. 2015 Apr 20. [Epub ahead of print] PubMed PMID: 25896863.

21: Harvey MJ, Gaies MG, Prosser LA. US and International In-Hospital Costs of Extracorporeal Membrane Oxygenation: a Systematic Review. Appl Health Econ Health Policy. 2015 Apr 18. [Epub ahead of print] PubMed PMID: 25894740.

22: Blommestein HM, Verelst SG, de Groot S, et. al. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. Eur J Haematol. 2015 Apr 18. [Epub ahead of print] PubMed PMID: 25892333.

23: Picavet E, Cassiman D, Simoens S. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses. J Clin Pharm Ther. 2015 Jun;40(3):304-7. Epub 2015 Apr 20. PubMed PMID: 25891411.

24: Cure S, Guerra I, Cammà C, et. al. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. J Med Econ. 2015 Apr 20:1-26. [Epub ahead of print] PubMed PMID: 25891129.

25: Capocci S, Smith C, Morris S, et. al. Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area. Eur Respir J. 2015 Apr 16. [Epub ahead of print] PubMed PMID: 25882810.

26: Mears J, Vynnycky E, Lord J, et. al. The prospective evaluation of the TB strain typing service in England: a mixed methods study. Thorax. 2015 Apr 16. [Epub ahead of print] PubMed PMID: 25882538.

27: Wu AC, Gay C, Rett MD, et. al. Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving. Pharmacogenomics. 2015 Apr;16(6):591-600. Epub 2015 Apr 16. PubMed PMID: 25880024.

28: Zucco F, Ciampichini R, Lavano A, et. al. Cost-Effectiveness and Cost-Utility Analysis of Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome: Results From the PRECISE Study. Neuromodulation. 2015 Apr 16. [Epub ahead of print] PubMed PMID: 25879722.

By CEA Registry Team on 5/4/2015 11:20 AM

The Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org) has now been updated to include published cost-utility studies or CUAs (studies that report findings in the form of cost per quality-adjusted life years (QALYs) gained) through 2013.  The database contains information on cost-utility analyses on a wide range of health and medical interventions published from 1976-2013, including information on almost 12,000 standardized cost-effectiveness ratios.

The current upload adds the following to the database:

•    332 cost-utility analyses articles published in 2013
•    847 cost-effectiveness ratios
•    1,665 utility weights

The full Registry now includes:

•    4,339 cost-utility analyses articles published from 1976 through 2013
•    11,880 cost-effectiveness ratios
•    16,946 utility weights

CEVR’s premium access subscribers can access both the entire CEA Registry and the Tufts National Coverage Determination database, which provides detailed information on each national coverage decision.  Premium access subscribers can conduct advanced searches of the Registry data.

If you are interested in becoming a sponsor, please contact Julie Lannon for more information.

Stay up-to-date on all the news from the CEA Registry by following us on Twitter @TuftsCEVR or Like Us on Facebook.

-    The CEA Registry Team

By CEA Registry Team on 4/17/2015 10:06 AM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Murajda L, Aichinger E, Pfaff G, et. al. Public health management of invasive meningococcal disease in Baden-Wuerttemberg, Germany, 2012: adherence to guidance and estimation of resources required as determined in a survey of local health authorities. BMC Public Health. 2015 Apr 12;15(1):371. PubMed PMID: 25881238.

2: Ramallo-Fariña Y, García-Pérez L, Castilla-Rodríguez I, et. al. Effectiveness and cost-effectiveness of knowledge transfer and behavior modification interventions in type 2 diabetes mellitus patients-the INDICA study: a cluster randomized controlled trial. Implement Sci. 2015 Apr 9;10(1):47. PubMed PMID: 25880498.

3: Hannemann PF, Essers BA, Schots JP, et. al. Functional outcome and cost-effectiveness of pulsed electromagnetic fields in the treatment of acute scaphoid fractures: a cost-utility analysis. BMC Musculoskelet Disord. 2015 Apr 11;16(1):84. PubMed PMID: 25880388.

4: Michaud K, Strand V, Shadick NA, et. al. Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. Rheumatology (Oxford). 2015 Apr 15. [Epub ahead of print] PubMed PMID: 25877911.

5: Prica A, Chan K, Cheung M. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis. Cancer. 2015 Apr 15. [Epub ahead of print] PubMed PMID: 25877511.

6: Tirani M, Meregaglia M, Melegaro A. Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme. PLoS One. 2015 Apr 13;10(4):e0123383. eCollection 2015. PubMed PMID: 25874805.

7: Kip M, Monteban H, Steuten L. Long-term cost-effectiveness of Oncotype DX(®) versus current clinical practice from a Dutch cost perspective. J Comp Eff Res. 2015 Apr 15:1-13. [Epub ahead of print] PubMed PMID: 25872415.

8: Cheung MC, Hay AE, Crump M, et. al. Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12. J Natl Cancer Inst. 2015 Apr 13;107(7). Print 2015 Jul. PubMed PMID: 25868579.

9: Aronsson M, Svennberg E, Rosenqvist M, et. al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace. 2015 Apr 12. [Epub ahead of print] PubMed PMID: 25868469.

10: Graham DM, Isaranuwatchai W, Habbous S, et. al. A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. Cancer. 2015 Apr 13. [Epub ahead of print] PubMed PMID: 25867018.

11: Forde GK, Chang J, Ziogas A, et. al. Costs of Treatment for Elderly Women with Advanced Ovarian Cancer in a Medicare Population. Gynecol Oncol. 2015 Apr 9. [Epub ahead of print] PubMed PMID: 25866323.

12: Vitale A, Spolverato G, Burra P, et. al. Cost-effectiveness of Pre-Transplant Sofosbuvir for Preventing Recurrent HCV Infection after Liver Transplantation. Transpl Int. 2015 Apr 11. [Epub ahead of print] PubMed PMID: 25865602.

13: Dewhurst E, Novakova B, Reuber M. A prospective service evaluation of acceptance and commitment therapy for patients with refractory epilepsy. Epilepsy Behav. 2015 Apr 10. [Epub ahead of print] PubMed PMID: 25864992.

14: Hirst A, Knight C, Hirst M, et. al. Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine. Eur J Health Econ. 2015 Apr 11. [Epub ahead of print] PubMed PMID: 25861916.

15: Lin L, Teng M, Zhao YJ, et. al. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly. Cardiovasc Drugs Ther. 2015 Apr 11. [Epub ahead of print] PubMed PMID: 25860556.

16: Brittenden J, Cotton SC, Elders A, et. al. Clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trial. Health Technol Assess. 2015 Apr;19(27):1-342. PubMed PMID: 25858333.

17: Nimdet K, Chaiyakunapruk N, Vichansavakul K, et. al. A Systematic Review of Studies Eliciting Willingness-to-Pay per Quality-Adjusted Life Year: Does It Justify CE Threshold? PLoS One. 2015 Apr 9;10(4):e0122760. eCollection 2015. PubMed PMID: 25855971.

18: Grieve R, Gomes M, Sweeting MJ, et. al. Endovascular strategy or open repair for ruptured abdominal aortic aneurysm: one-year outcomes from the IMPROVE randomized trial. Eur Heart J. 2015 Apr 7. [Epub ahead of print] PubMed PMID: 25855369.

19: Sturkenboom IH, Hendriks JC, Graff MJ, et. al. Economic evaluation of occupational therapy in Parkinson's disease: A randomized controlled trial. Mov Disord. 2015 Apr 8. [Epub ahead of print] PubMed PMID: 25854809.

20: Huetson P, Palmer JL, Levorsen A, et. al. Cost-effectiveness of once-daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with Type 2 diabetes in Norway. J Med Econ. 2015 Apr 8:1-30. [Epub ahead of print] PubMed PMID: 25853868.

21: Wu JX, Beni CE, Zanocco K, et. al. Cost-Effectiveness of Long-Term Every Three-Year Versus Annual Postoperative Surveillance for Low Risk Papillary Thyroid Cancer. Thyroid. 2015 Apr 8. [Epub ahead of print] PubMed PMID: 25851702.

22: Stevenson M, Pandor A, Stevens JW, et. al. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2015 Apr 8. [Epub ahead of print] PubMed PMID: 25851485.

23: Letchumanan MG, Coyte PC, Loutfy M. An economic evaluation of conception strategies for heterosexual serodiscordant couples where the male partner is HIV-positive. Antivir Ther. 2015 Apr 7. [Epub ahead of print] PubMed PMID: 25849113.

24: Cure S, Guerra I, Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat. 2015 Apr 7. [Epub ahead of print] PubMed PMID: 25847572.

25: Twigg MJ, Wright D, Barton GR, et. al. The four or more medicines (FOMM) support service: results from an evaluation of a new community pharmacy service aimed at over-65s. Int J Pharm Pract. 2015 Apr 6. [Epub ahead of print] PubMed PMID: 25847545.

26: Genders TS, Petersen SE, Pugliese F, et. al. The optimal imaging strategy for patients with stable chest pain: a cost-effectiveness analysis. Ann Intern Med. 2015 Apr 7;162(7):474-84. PubMed PMID: 25844996.

27: Palace J, Duddy M, Bregenzer T, et. al. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurol. 2015 Apr 1. [Epub ahead of print] PubMed PMID: 25841667.

28: Petrie J, Easton S, Naik V, et. al. Hospital costs of out-of-hospital cardiac arrest patients treated in intensive care; a single centre evaluation using the national tariff-based system. BMJ Open. 2015 Apr 2;5(4):e005797. PubMed PMID: 25838503.

29: Sowa PM, Downes MJ, Gordon LG. Cost-effectiveness of dual energy X-ray absorptiometry (DXA) plus anti-resorptive treatment in Australian women with breast cancer who receive aromatase inhibitors. J Bone Miner Metab. 2015 Apr 3. [Epub ahead of print] PubMed PMID: 25837431.

30: Neilson AR, Bruhn H, Bond CM, et. al. Pharmacist-led management of chronic pain in primary care: costs and benefits in a pilot randomised controlled trial. BMJ Open. 2015 Apr 1;5(4):e006874. PubMed PMID: 25833666.

31: Retèl VP, van den Boer C, Steuten LM, et. al. Cost-effectiveness of heat and moisture exchangers compared to usual care for pulmonary rehabilitation after total laryngectomy in Poland. Eur Arch Otorhinolaryngol. 2015 Apr 2. [Epub ahead of print] PubMed PMID: 25832966.

32: Tannenbaum C, Diaby V, Singh D, et. al. Sedative-Hypnotic Medicines and Falls in Community-Dwelling Older Adults: A Cost-Effectiveness (Decision-Tree) Analysis from a US Medicare Perspective. Drugs Aging. 2015 Apr;32(4):305-14. PubMed PMID: 25825121.

33: Pulikottil-Jacob R, Connock M, Kandala NB, et. al. Cost effectiveness of total hip arthroplasty in osteoarthritis: comparison of devices with differing bearing surfaces and modes of fixation. Bone Joint J. 2015 Apr;97-B(4):449-57. PubMed PMID: 25820881.

34: Krishnan NM, Purnell C, Nahabedian MY, et. al. The Cost Effectiveness of the DIEP Flap Relative to the Muscle-Sparing TRAM Flap in Postmastectomy Breast Reconstruction. Plast Reconstr Surg. 2015 Apr;135(4):948-58. PubMed PMID: 25811560.

35: Barzi A, Sadeghi S, Kattan MW, et. al. Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst. 2015 Mar 20;107(4). Print 2015 Apr. PubMed PMID: 25794514.

36: Laires PA, Ejzykowicz F, Hsu TY, et. al. Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal. J Med Econ. 2015 Apr 10:1-8. [Epub ahead of print] PubMed PMID: 25788039.

37: Varier RU, Biltaji E, Smith KJ, et. al. Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Infect Control Hosp Epidemiol. 2015 Apr;36(4):438-44. PubMed PMID: 25782899.

38: Nuijten M, Roggeri DP, Roggeri A, et. al. Health economic evaluation of paricalcitol(®) versus cincalcet + calcitriol (oral) in Italy. Clin Drug Investig. 2015 Apr;35(4):229-38. PubMed PMID: 25724153.

39: Slaman J, van den Berg-Emons R, Tan SS, et. al. Cost-utility of a lifestyle intervention in adolescents and young adults with spastic cerebral palsy. J Rehabil Med. 2015 Apr 7;47(4):338-45. PubMed PMID: 25678311.

40: Rubio-Terrés C, Soria JM, Morange PE, et. al. Economic Analysis of Thrombo inCode, a Clinical-Genetic Function for Assessing the Risk of Venous Thromboembolism. Appl Health Econ Health Policy. 2015 Apr;13(2):233-42. PubMed PMID: 25652150.

41: Tuffaha HW, Roberts S, Chaboyer W, et. al. Cost-Effectiveness and Value of Information Analysis of Nutritional Support for Preventing Pressure Ulcers in High-risk Patients: Implement Now, Research Later. Appl Health Econ Health Policy. 2015 Apr;13(2):167-79. PubMed PMID: 25650349.

42: Lønne G, Johnsen LG, Aas E, et. al. Comparing Cost-effectiveness of X-Stop With Minimally Invasive Decompression in Lumbar Spinal Stenosis: A Randomized Controlled Trial. Spine (Phila Pa 1976). 2015 Apr 15;40(8):514-20. PubMed PMID: 25608246.

43: Romanus D, Cardarella S, Cutler D, et. al. Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer. J Thorac Oncol. 2015 Apr;10(4):586-94. PubMed PMID: 25590606.

44: Huang YL, Lasry A, Hutchinson AB, et. al. A Systematic Review on Cost Effectiveness of HIV Prevention Interventions in the United States. Appl Health Econ Health Policy. 2015 Apr;13(2):149-56. PubMed PMID: 25536927.

45: Hamid R, Loveman C, Millen J, et. al. Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX(®)) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective. Pharmacoeconomics. 2015 Apr;33(4):381-93. PubMed PMID: 25526842.

46: Matros E, Albornoz CR, Razdan SN, et. al. Cost-Effectiveness Analysis of Implants versus Autologous Perforator Flaps Using the BREAST-Q. Plast Reconstr Surg. 2015 Apr;135(4):937-46. PubMed PMID: 25517411.

47: Offodile AC 2nd, Chatterjee A, Vallejo S, et. al. A cost-utility analysis of the use of preoperative computed tomographic angiography in abdomen-based perforator flap breast reconstruction. Plast Reconstr Surg. 2015 Apr;135(4):662e-9e. PubMed PMID: 25517410.

48: Janzic A, Kos M. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics. 2015 Apr;33(4):395-408. PubMed PMID: 25512096.

49: Delea TE, Amdahl J, Wang A, et. al. Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada. Pharmacoeconomics. 2015 Apr;33(4):367-80. PubMed PMID: 25488880.

50: Zhang W, Islam N, Ma C, et. al. Systematic review of cost-effectiveness analyses of treatments for psoriasis. Pharmacoeconomics. 2015 Apr;33(4):327-40. PubMed PMID: 25475964.

51: Huang H, Taylor DC, Carson RT, et. al. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States. J Med Econ. 2015 Apr;18(4):283-294. PubMed PMID: 25333331.

52: Adogwa O, Parker SL, Shau D, et. al. Cost Per Quality-adjusted Life Year Gained of Revision Fusion for Lumbar Pseudoarthrosis: Defining the Value of Surgery. J Spinal Disord Tech. 2015 Apr;28(3):101-5. PubMed PMID: 24999554.

53: Chatterjee A, Krishnan NM, Rosen JM. Complex ventral hernia repair using components separation with or without biologic mesh: a cost-utility analysis. Ann Plast Surg. 2015 Apr;74(4):471-8. PubMed PMID: 24051454.

By CEA Registry Team on 4/6/2015 12:52 PM

By Teja Thorat, MSc, MPH

In our recently published paper in Value in Health Regional Issues, “The State of Cost-Utility Analyses in Asia: A Systematic Review,” my colleagues and I review and evaluate published, English-language, cost-utility analyses (CUAs) targeting populations in Asia.(1)

We analyzed data from the Tufts Medical Center Cost-Effectiveness Analysis Registry to summarize study features from these CUAs, such as country of study, disease area researched, study funder, and type of intervention. We also compared the Asian CUAs to CUAs focusing on non-Asian population across study features, methodological characteristics, and reporting practices, such as study perspective, discounting of costs and health benefits, time horizon, funding source, acceptability curves, and sensitivity analyses.

Asian CUAs account for 5.1% (n=175) of the total CUAs present in the CEA Registry from 2000-2012 (n=3,414). The number of Asian CUAs has steadily grown over the past years from 19 CUAs published in 2000-2004 to 107 CUAs in 2009-2012. Asian CUAs were most often set in Japan (33.1%), followed by Taiwan (15.4%), China (14.9%), Thailand (8.0%), and South Korea (6.9%).

Figure 1. Asian cost-utility analyses by country of study, 2000-2012.
 

Figure 1. Asian cost-utility analyses by country of study, 2000-2012.

The most common diseases researched were cancer (24.6%) followed by infectious diseases (13.7%) and cardiovascular disease (8.6%). Most studies were funded by government agencies (29.1%) followed by pharmaceutical and device companies (21.7%). Asian CUAs focused mainly on pharmaceutical treatments (56%) followed by screening programs (19.4%) and immunizations (12.0%). Furthermore, a higher proportion of Asian CUAs evaluated primary prevention practices such as immunizations and screenings compared to non-Asian CUAs (21.7% vs. 16.5%, p=0.07). Also, fewer Asian CUAs were sponsored by pharmaceutical companies compared to non-Asian CUAs (p=0.001). In comparing the methodological and reporting practices between the two groups, we found that the majority of Asian CUAs adhered to good reporting practices; however, they lagged in reporting sensitivity analyses, disclosing funding status, and stating the currency year.  A full description of the CEA Registry and other recent trends can be found here.(2)

References

1.    Thorat T, Lin PJ, Neumann PJ. The State of Cost-Utility Analyses in Asia: A Systematic Review. Value Health Regional Issues. 2015 May 7–13.
2.    Neumann PJ, Thorat T, Shi J, et. al. The Changing Face of the Cost Utility Literature, 1990-2012. Value in Health 2015. 18(2):271-277.
 

By CEA Registry Team on 4/3/2015 12:52 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Moran PS, Teljeur C, Masterson S, et. al. Cost-effectiveness of a national public access defibrillation programme. Resuscitation. 2015 Mar 28. [Epub ahead of print] PubMed PMID: 25828922.

2: Hogendoorn W, Lavida A, Hunink MG, et. al. Cost-effectiveness of endovascular repair, open repair, and conservative management of splenic artery aneurysms. J Vasc Surg. 2015 Mar 28. [Epub ahead of print] PubMed PMID: 25827968.

3: Bortoletto P, Einerson BD, Miller ES, et. al. A Cost-Effectiveness Analysis Of Morcellation Hysterectomy For Fibroids. J Minim Invasive Gynecol. 2015 Mar 28. [Epub ahead of print] PubMed PMID: 25827327.

4: Huntington SF, Svoboda J, Doshi JA. Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. J Clin Oncol. 2015 Mar 30. [Epub ahead of print] PubMed PMID: 25823735.

5: Linas BP, Barter DM, Morgan JR, et. al. The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection. Ann Intern Med. 2015 Mar 30. [Epub ahead of print] PubMed PMID: 25820703.

6: Plumpton CO, Brown I, Reuber M, et. al. Economic evaluation of a behavior-modifying intervention to enhance antiepileptic drug adherence. Epilepsy Behav. 2015 Mar 26. [Epub ahead of print] PubMed PMID: 25819948.

7: Yang JJ, Thanataveerat A, Green PH, et. al. Cost Effectiveness of Routine Duodenal Biopsy Analysis for Celiac Disease During Endoscopy for Gastroesophageal Reflux. Clin Gastroenterol Hepatol. 2015 Mar 25. [Epub ahead of print] PubMed PMID: 25818076.

8: Charokopou M, McEwan P, Lister S, et. al. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. Diabet Med. 2015 Mar 28. [Epub ahead of print] PubMed PMID: 25817050.

9: Zhang S, Rust G, Cardarelli K, et. al. Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection. AIDS Care. 2015 Mar 27:1-7. [Epub ahead of print] PubMed PMID: 25814041.

10: Ito K, Leslie WD. Cost-effectiveness of fracture prevention in rural women with limited access to dual-energy X-ray absorptiometry. Osteoporos Int. 2015 Mar 26. [Epub ahead of print] PubMed PMID: 25807913.

11: Shen HJ, Hsu CT, Tung TH. Economic and medical benefits of ultrasound screenings for gallstone disease. World J Gastroenterol. 2015 Mar 21;21(11):3337-43. PubMed PMID: 25805942.

12: Morris S, Gurusamy KS, Sheringham J, et. al. Cost-Effectiveness Analysis of Endoscopic Ultrasound versus Magnetic Resonance Cholangiopancreatography in Patients with Suspected Common Bile Duct Stones. PLoS One. 2015 Mar 23;10(3):e0121699. eCollection 2015. PubMed PMID: 25799113.

13: Yates CJ, Chauchard MA, Liew D, et. al. Bridging the Osteoporosis Treatment Gap: Performance and Cost-Effectiveness of a Fracture Liaison Service. J Clin Densitom. 2015 Mar 18. [Epub ahead of print] PubMed PMID: 25797867.

14: Berndt N, Bolman C, Lechner L, et. al. Economic evaluation of a telephone- and face-to-face-delivered counseling intervention for smoking cessation in patients with coronary heart disease. Eur J Health Econ. 2015 Mar 22. [Epub ahead of print] PubMed PMID: 25796578.

15: Tolley K, Kemmett D, Thybo S, et. al. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective. Eur J Health Econ. 2015 Mar 21. [Epub ahead of print] PubMed PMID: 25795391.

16: Athanasakis K, Tarantilis F, Tsalapati K, et. al. Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece. Rheumatol Int. 2015 Mar 21. [Epub ahead of print] PubMed PMID: 25794569.

17: Wolfson LJ, Walker A, Hettle R, et. al. Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK. PLoS One. 2015 Mar 20;10(3):e0120763. eCollection 2015. PubMed PMID: 25794045.

18: Gharaibeh M, McBride A, Bootman JL, et. al. Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer. Br J Cancer. 2015 Mar 19. [Epub ahead of print] PubMed PMID: 25791875.

19: Muennig PA, Quan R, Chiuzan C, et. al. Considering Whether Medicaid Is Worth the Cost: Revisiting the Oregon Health Study. Am J Public Health. 2015 Mar 19:e1-e5. [Epub ahead of print] PubMed PMID: 25790389.

20: Laires PA, Ejzykowicz F, Hsu TY, et. al. Cost-effectiveness of adding ezetimibe to atorvastatin versus switching to rosuvastatin therapy in Portugal. J Med Econ. 2015 Mar 19:1-24. [Epub ahead of print] PubMed PMID: 25788039.

21: Zhou J, Zhao R, Wen F, et. al. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Med Oncol. 2015 Apr;32(4):580. Epub 2015 Mar 19. PubMed PMID: 25788034.

22: Roberts ET, Horne A, Martin SS, et. al. Cost-Effectiveness of Coronary Artery Calcium Testing for Coronary Heart and Cardiovascular Disease Risk Prediction to Guide Statin Allocation: The Multi-Ethnic Study of Atherosclerosis (MESA). PLoS One. 2015 Mar 18;10(3):e0116377. eCollection 2015. PubMed PMID: 25786208.

23: Joensuu JT, Huoponen S, Aaltonen KJ, et. al. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One. 2015 Mar 17;10(3):e0119683. eCollection 2015. PubMed PMID: 25781999.

24: Yeh JM, Hur C, Ward Z, et. al. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut. 2015 Mar 16. [Epub ahead of print] PubMed PMID: 25779597.

25: Rein DB, Wittenborn JS, Smith BD, et. al. The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus. Clin Infect Dis. 2015 Mar 16. [Epub ahead of print] PubMed PMID: 25778747.

26: Najafzadeh M, Andersson K, Shrank WH, et. al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015 Mar 17;162(6):407-19. PubMed PMID: 25775313.

27: Chhatwal J, Kanwal F, Roberts MS, et. al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015 Mar 17;162(6):397-406. PubMed PMID: 25775312.

28: Lacasse Y, Bernard S, Martin S, et. al. Utility Scores In Patients With Oxygen-Dependent COPD: A Case-Control Study. COPD. 2015 Mar 16. [Epub ahead of print] PubMed PMID: 25774981.

29: Nelson RE, Angelovic AW, Nelson SD, et. al. An Economic Analysis of Adherence Engineering to Improve Use of Best Practices During Central Line Maintenance Procedures. Infect Control Hosp Epidemiol. 2015 Mar 16:1-7. [Epub ahead of print] PubMed PMID: 25772996.

30: Slof J, Ruiz L, Vila C. Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy. Expert Rev Pharmacoecon Outcomes Res. 2015 Mar 16:1-13. [Epub ahead of print] PubMed PMID: 25771713.

31: Hofmarcher T, Borg S. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. J Med Econ. 2015 Mar 31:1-10. [Epub ahead of print] PubMed PMID: 25766863.

By CEA Registry Team on 3/23/2015 8:55 AM

By Cayla Saret, B.A. and Peter Neumann, Sc.D.

In our newly published paper in Value in Health, we (along with colleagues) investigated trends in the cost-utility literature.(1) Cost-utility analyses (CUAs) measure the incremental costs and health benefits of interventions compared with alternatives. Our review reveals considerable growth and some change in the cost-utility literature in recent years.

The number of CUAs published soared over the time period we studied, from 34 per year from 1990 to 1999 to 431 per year from 2010 to 2012. We examined the changing characteristics of these analyses.

“The number of CUAs published has soared from 34 per year (1990-1999) to 431 per year (2010-2012).” [Tweet this]

 Figure 1. Growth in the number of CUAs. Source: Neumann et. al. 2015.

Figure 1. Growth in the number of CUAs. Source: Neumann et. al. 2015.

We analyzed data from the Tufts Medical Center Cost-Effectiveness Analysis Registry, a database containing more than 3,700 English-language CUAs published in peer-reviewed journals through 2012 at the time of the study (updates are provided regularly).

The number of studies from the United States fell from 61% of the literature during 1990 to 1999 to 35% during 2010 to 2012. The number of studies focused on low- and middle-income countries increased, although still small compared with those focused on higher-income countries.  The number of journals publishing CUAs increased from 58 in 2000 to 251 in 2012. In 2012, 60 journals published CUAs for the first time. (See here for the complete list of journals publishing CUAs.)

Fig. 3. Distribution of CUAs by income of country (2000–2012), using 2012 World Bank income groups. Source: Neumann et. al. 2015. 


Fig. 3. Distribution of CUAs by income of country (2000–2012), using 2012 World Bank income groups.(2) High-income countries; middle-income countries; low-income countries. Source: Neumann et. al. 2015.

The most common disease areas examined by CUAs include cardiovascular diseases (18%), cancer (15%), and infectious diseases (15%). The field continues to focus in large part on pharmaceuticals (47%). The majority of CUAs have focused on treatments (65%), followed by secondary (19%) and primary (16%) prevention. Burden of disease and number of CUAs published vary by region; however, in all regions, injuries have a high burden but relatively few CUAs.


References

1.    Neumann PJ, Thorat T, Shi J, et. al. The Changing Face of the Cost Utility Literature, 1990-2012. Value in Health 2015. 18(2):271-277.
2.    Drummond MF, Sculpher MJ, Torrance GW, et. al. Methods for the Economic Evaluation of Health Care Programmes (3rd ed). Oxford University Press, Oxford, UK. 2014.

By CEA Registry Team on 3/18/2015 9:21 AM

By Yue Zhong, MD, PhD

In our new Value in Health paper, “Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence,” my colleagues and I assess the opportunities for better investing health care resources for diabetes in the United States.(1) We found that most diabetes interventions with available cost-utility analyses (CUAs) may offer good value. Increased use of these interventions could potentially improve health outcomes while reducing costs.

First, we reviewed all diabetes-related CUAs catalogued in the Tufts Cost Effectiveness Analysis Registry.  The review included 196 diabetes CUAs published through the end of 2012 that reported 497 cost-effectiveness ratios. Most (73%) of the interventions were cost-saving or achieved health improvements at a cost of less than $50,000 per quality-adjusted life year (QALY), a commonly used threshold for cost-effectiveness. The median cost-effectiveness ratio was $15,400 per QALY (2012 $US).

Next, we used Humedica electronic medical records (EMRs) to explore possible gains from reallocating resources from low-value interventions for diabetes (those that increase costs and make health worse) to high-value interventions (those that improve health and reduce costs). We identified four high value interventions (e.g., intensive hypertension control among diabetes patients with hypertension) with utilization data available. The results indicate there is substantial opportunity to shift spending to these high value interventions.

Of 400,000 diabetic patients in the Humedica EMR database, we identified 7,907 eligible patients using the low-value interventions. In this population, up to 7,117 diabetes patients could move from low- to high-value treatments, saving more than $12 million and gaining more than 1,900 QALYs.

We acknowledge at the outset that this is an exploratory analysis, and that the results may not be readily scaled to the national level. Our main objective was to demonstrate the principle of using real-world data to identify opportunities for saving money and improving health by reinvesting.  Both patients and the overall health care system could potentially benefit from shifting to the greater use of services that have demonstrated greater health benefits and lower costs.


References

1.    Yue Z, Lin P-J, Cohen JT, et. al. Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence. Value in Health 2015;18(2):308-314.

By CEA Registry Team on 3/16/2015 2:12 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Vavken P, Sadoghi P, Palmer M, et. al. Platelet-Rich Plasma Reduces Retear Rates After Arthroscopic Repair of Small- and Medium-Sized Rotator Cuff Tears but Is Not Cost-Effective. Am J Sports Med. 2015 Mar 12. [Epub ahead of print] PubMed PMID: 25767267.

2: Bogosian A, Chadwick P, Windgassen S, et. al. Distress improves after mindfulness training for progressive MS: A pilot randomised trial. Mult Scler. 2015 Mar 12. [Epub ahead of print] PubMed PMID: 25767124.

3: Hofmarcher T, Borg S. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. J Med Econ. 2015 Mar 12:1-20. [Epub ahead of print] PubMed PMID: 25766863.

4: Minion LE, Bai J, Monk BJ, et. al. A markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecol Oncol. 2015 Mar 9. [Epub ahead of print] PubMed PMID: 25766118.

5: de Wit GA, Over EA, Schmid BV, et. al. Chlamydia screening is not cost-effective at low participation rates: evidence from a repeated register-based implementation study in the Netherlands. Sex Transm Infect. 2015 Mar 10. [Epub ahead of print] PubMed PMID: 25759475.

6: Bongers ML, Coupé VM, De Ruysscher D, et. al. Individualized positron emission tomography-based isotoxic accelerated radiation  therapy is cost-effective compared with conventional radiation therapy: a model-based evaluation. Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):857-65. PubMed PMID: 25752401.

7: Williams MA, Williamson EM, Heine PJ, et. al. Strengthening And stretching for Rheumatoid Arthritis of the Hand (SARAH). A randomised controlled trial and economic evaluation. Health Technol Assess. 2015 Mar;19(19):1-222. PubMed PMID: 25748549.

8: Thampi N, Gurol-Urganci I, Crowcroft NS, et. al. Pertussis Post-Exposure Prophylaxis among Household Contacts: A Cost-Utility Analysis. PLoS One. 2015 Mar 6;10(3):e0119271. eCollection 2015. PubMed PMID: 25747269.

9: Snarski E, Szmurło D, Hałaburda K, et. al. An economic analysis of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of new onset type 1 diabetes. Acta Diabetol. 2015 Mar 6. [Epub ahead of print] PubMed PMID: 25744552.

10: Pérez A, Mezquita Raya P, Ramírez de Arellano A, et. al. Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin. Diabetes Ther. 2015 Mar 6. [Epub ahead of print] PubMed PMID: 25742705.

11: Kaplan RI, De Moraes CG, Cioffi GA, et. al. Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment. JAMA Ophthalmol. 2015 Mar 5. [Epub ahead of print] PubMed PMID: 25741886.

12: Mirsaeedi-Farahani K, Halpern CH, Baltuch GH, et. al. Deep brain stimulation for Alzheimer disease: a decision and cost-effectiveness analysis. J Neurol. 2015 Mar 6. [Epub ahead of print] PubMed PMID: 25740662.

13: Makras P, Athanasakis K, Boubouchairopoulou N, et. al. Cost-effective osteoporosis treatment thresholds in Greece. Osteoporos Int. 2015 Mar 5. [Epub ahead of print] PubMed PMID: 25740208.

14: Ghomrawi HM, Eggman AA, Pearle AD. Effect of age on cost-effectiveness of unicompartmental knee arthroplasty compared with total knee arthroplasty in the u.s. J Bone Joint Surg Am. 2015 Mar 4;97(5):396-402. PubMed PMID: 25740030.

15: Chowdhury EK, Ademi Z, Moss JR, et. al; Second Australian National Blood Pressure Study Management Committee. Cost-utility of Angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly australians considering diabetes as comorbidity. Medicine (Baltimore). 2015 Mar;94(9):e590. PubMed PMID: 25738481.

16: Soneji S, Yang J. New analysis reexamines the value of cancer care in the United States compared to Western europe. Health Aff (Millwood). 2015 Mar 1;34(3):390-7. PubMed PMID: 25732488.

17: Chatterjee A, Ramkumar DB, Dawli TB, et. al. The Use of Mesh versus Primary Fascial Closure of the Abdominal Donor Site When Using a Transverse Rectus Abdominis Myocutaneous Flap for Breast Reconstruction: A Cost-Utility Analysis. Plast Reconstr Surg. 2015 Mar;135(3):682-9. PubMed PMID: 25719690.

18: Harrison M, Collins CD. Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis? Infect Control Hosp Epidemiol. 2015 Mar;36(3):265-72. PubMed PMID: 25695167.

19: Parker SL, McGirt MJ. Determination of the minimum improvement in pain, disability, and health state associated with cost-effectiveness: introduction of the concept of minimum cost-effective difference. Neurosurgery. 2015 Mar;76 Suppl 1:S64-70. PubMed PMID: 25692370.

20: Zhang C, Ke W, Gao Y, et. al. Cost-Effectiveness Analysis of Antiviral Therapies for Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients in China. Clin Drug Investig. 2015 Mar;35(3):197-209. PubMed PMID: 25672930.

21: Black WC. Computed Tomography Screening for Lung Cancer in the National Lung Screening Trial: A Cost-effectiveness Analysis. J Thorac Imaging. 2015 Mar;30(2):79-87. PubMed PMID: 25635704.

22: Lee BY, Bartsch SM, Brown ST, et. al. Quantifying the economic value and quality of life impact of earlier influenza vaccination. Med Care. 2015 Mar;53(3):218-29. PubMed PMID: 25590676.

23: Mensch A, Stock S, Stollenwerk B, et. al. Cost effectiveness of rivaroxaban for stroke prevention in german patients with atrial fibrillation. Pharmacoeconomics. 2015 Mar;33(3):271-83. PubMed PMID: 25404426.

By CEA Registry Team on 3/2/2015 3:19 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Nuijten M, Roggeri DP, Roggeri A, et. al. Health Economic Evaluation of Paricalcitol(®) Versus Cincalcet + Calcitriol (Oral) in Italy. Clin Drug Investig. 2015 Feb 28. [Epub ahead of print] PubMed PMID: 25724153.

2: Ferguson T, Xu Y, Gunasekara R, et. al. The Cost Effectiveness of Erythropoietin-Stimulating Agents for Treating Anemia in Patients on Dialysis: A Systematic Review. Am J Nephrol. 2015  Feb 26;41(2):89-97. [Epub ahead of print] PubMed PMID: 25721696.

3: Littlewood KJ, Ouwens MJ, Sauboin C, et. al. Cost-Effectiveness of Routine Varicella Vaccination Using the Measles, Mumps, Rubella and Varicella Vaccine in France: An Economic Analysis Based on a Dynamic Transmission Model for Varicella and Herpes Zoster. Clin Ther. 2015 Feb 23. [Epub ahead of print] PubMed PMID: 25721380.

4: Leung RM, Smith TL, Rudmik L. Developing a Laddered Algorithm for the Management of Intractable Epistaxis: A Risk Analysis. JAMA Otolaryngol Head Neck Surg. 2015 Feb 26. [Epub ahead of print] PubMed PMID: 25719360.

5: Schawo S, van der Kolk A, Bouwmans C, et. al. Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed? Pharmacoeconomics. 2015 Feb 26. [Epub ahead of print] PubMed PMID: 25715975.

6: You JH, Ming WK, Chan PK. Cost-effectiveness of Quadrivalent Influenza Vaccine in Hong Kong - A decision analysis. Hum Vaccin Immunother. 2015 Feb 25:0. [Epub ahead of print] PubMed PMID: 25714506.

7: Hu Y, Shah P, Stukenborg GJ, et. al. Utility of sentinel lymph node biopsy for solitary dermal melanomas. J Surg Oncol. 2015 Feb 24. [Epub ahead of print] PubMed PMID: 25712273.

8: Farag I, Howard K, Hayes AJ, et. al. Cost-effectiveness of a Home-Exercise Program Among Older People After Hospitalization. J Am Med Dir Assoc. 2015 Feb 18. [Epub ahead of print] PubMed PMID: 25703448.

9: Hoerger TJ, Crouse WL, Zhuo X, et. al. Medicare's Intensive Behavioral Therapy for Obesity: An Exploratory Cost-Effectiveness Analysis. Am J Prev Med. 2015 Feb 19. [Epub ahead of print] PubMed PMID: 25703178.

10: Lee EK, Wong WW, Trudeau ME, et. al. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. Breast Cancer Res Treat. 2015 Feb;150(1):169-80. Epub 2015 Feb 19. PubMed PMID: 25694355.

11: Naing C, Poovorawan Y, Mak JW, et. al. Cost-utility analysis of an adjunctive recombinant activated factor VIIa for on-demand treatment of bleeding episodes in dengue haemorrhagic fever. Blood Coagul Fibrinolysis. 2015  Feb 16. [Epub ahead of print] PubMed PMID: 25692521.

12: Goldstein DA, Chen Q, Ayer T, et. al. First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States-Based Cost-Effectiveness Analysis. J Clin Oncol. 2015 Feb 17. [Epub ahead of print] PubMed PMID: 25691669.

13: Earnshaw SR, Graham CN, McDade CL, et. al. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015 Feb 16. [Epub ahead of print] PubMed PMID: 25688580.

14: Pyne JM, Fortney JC, Mouden S, et. al. Cost-Effectiveness of On-Site Versus Off-Site Collaborative Care for Depression in Rural FQHCs. Psychiatr Serv. 2015 Feb 17:appips201400186. [Epub ahead of print] PubMed PMID: 25686811.

15: Domínguez-Ortega J, Phillips-Anglés E, Barranco P, Quirce S. Cost-effectiveness of asthma therapy: a comprehensive review. J Asthma. 2015 Feb 20:1-9. [Epub ahead of print] PubMed PMID: 25539023.

By CEA Registry Team on 2/24/2015 12:02 PM

By James Chambers, Ph.D.

US payers make coverage and reimbursement decisions for drugs upon their FDA approval.  These decisions are made before the supporting evidence has fully matured, and typically before cost-effectiveness evidence is available.  This lag between FDA approval and publication of cost-effectiveness evidence can hamper payers from accounting for value in coverage and reimbursement decisions. 

In a new paper, published as a special report in Expert Review of Pharmacoeconomics and Outcomes Research, we examined this lag, and whether it has changed over time.(1)  For drugs approved for the first time by the FDA from 2000 through 2010, we searched the CEA Registry (www.cearegistry.org) for relevant cost-utility analyses (CUAs), and for each identified study we determined the date of first publication.  Then, for each drug, we determined whether a CUA was published in the three years following FDA approval.  We used a 3-year period as this was the maximum interval between the most recently approved drug in the dataset and the end of the search period.

Of all drugs approved in our time period, 23% (62/274) were associated with a CUA within the three years following approval.  The lag before CUA publication has decreased over time, and compared with drugs approved from 2000 to 2003, the lag was shorter for drugs approved from 2004 to 2006 (p=0.06), and from 2007 to 2010 (p<0.01) (Figure 1).

Our findings are encouraging, and illustrate that payers now have somewhat more rapid access to evidence of value than they did previously.  Nevertheless, we found that many drugs did not have an accompanying CUA, and of those that did, there was still a lengthy delay for several before the study was available.  We are hopeful that, as demand for evidence of value grows, the lag between FDA approval and publication of a CUA will decrease further.  



1.    Chambers JD, Thorat T, Pyo J, Neumann PJ. The lag from FDA approval to published cost-utility evidence. Expert Rev Pharmacoecon Outcomes Res. 2015 Jan 12:1-4

By CEA Registry Team on 2/18/2015 2:53 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials

1: Slaman J, van den Berg-Emons R, Tan SS, et. al. Cost-utility of a lifestyle intervention in adolescents and young adults with spastic cerebral palsy. J Rehabil Med. 2015 Feb 12. [Epub ahead of print] PubMed PMID: 25678311.

2: Leidner AJ, Chesson HW, Xu F, et. al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology. 2015 Feb 11. [Epub ahead of print] PubMed PMID: 25677072.

3: Ball S, Vickery J, Hobart J, et. al. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technol Assess. 2015 Feb;19(12):1-188. PubMed PMID: 25676540.

4: Lao C, Brown C, Rouse P, et. al. Economic evaluation of prostate cancer screening: a systematic review. Future Oncol. 2015 Feb;11(3):467-77. PubMed PMID: 25675126.

5: Zhang C, Ke W, Gao Y, et. al. Cost-Effectiveness Analysis of Antiviral Therapies for Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients in China. Clin Drug Investig. 2015 Feb 12. [Epub ahead of print] PubMed PMID: 25672930.

6: Gyrd-Hansen D, Olsen KR, Bollweg K, et. al. Cost-effectiveness estimate of prehospital thrombolysis: Results of the PHANTOM-S Study. Neurology. 2015 Feb 11. [Epub ahead of print] PubMed PMID: 25672925.

7: Alberti A, Giudice P, Gelera A, et. al. Understanding the economic impact of intravascular ultrasound (IVUS). Eur J Health Econ. 2015 Feb 11. [Epub ahead of print] PubMed PMID: 25669755.

8: Retèl VP, van der Molen L, Steuten LM, et. al. A cost-effectiveness analysis of using TheraBite in a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy. Eur Arch Otorhinolaryngol. 2015 Feb 11. [Epub ahead of print] PubMed PMID: 25666587.

9: Spolverato G, Vitale A, Ejaz A, et. al. The Relative Net Health Benefit of Liver Resection, Ablation, and Transplantation for Early Hepatocellular Carcinoma. World J Surg. 2015 Feb 10. [Epub ahead of print] PubMed PMID: 25665675.

10: Bouland AJ, Risko N, Lawner BJ, et. al. The Price of a Helping Hand: Modeling the Outcomes and Costs of Bystander CPR. Prehosp Emerg Care. 2015 Feb 9. [Epub ahead of print] PubMed PMID: 25665010.

11: Stevens KJ. How Well Do the Generic Multi-attribute Utility Instruments Incorporate Patient and Public Views Into Their Descriptive Systems? Patient. 2015 Feb 8. [Epub ahead of print] PubMed PMID: 25663152.

12: Tao L, Wilson EC, Wareham NJ, et. al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabet Med. 2015 Feb 6. [Epub ahead of print] PubMed PMID: 25661661.

13: Cowper PA, Pan W, Anstrom KJ, et. al. Economic Analysis of Ticagrelor Therapy From a U.S. Perspective: Results From the PLATO Study. J Am Coll Cardiol. 2015 Feb 10;65(5):465-76. PubMed PMID: 25660925.

14: Song DL, Altice FL, Copenhaver MM, et. al. Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States. PLoS One. 2015 Feb 6;10(2):e0116694. eCollection 2015. PubMed PMID: 25658949.

15: Fergenbaum J, Bermingham S, Krahn M, et. al. Care in the Home for the Management of Chronic Heart Failure: Systematic Review and Cost-Effectiveness Analysis. J Cardiovasc Nurs. 2015 Feb 5. [Epub ahead of print] PubMed PMID: 25658188.

16: Saret CJ, Winn A, Shah G, et. al. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood. 2015 Feb 5. [Epub ahead of print] PubMed PMID: 25655601.

17: Rubio-Terrés C, Soria JM, Morange PE, et. al. Economic Analysis of Thrombo inCode, a Clinical-Genetic Function for Assessing the Risk of Venous Thromboembolism. Appl Health Econ Health Policy. 2015 Feb 5. [Epub ahead of print] PubMed PMID: 25652150.

18: Tuffaha HW, Roberts S, Chaboyer W, et. al. Cost-Effectiveness and Value of Information Analysis of Nutritional Support for Preventing Pressure Ulcers in High-risk Patients: Implement Now, Research Later. Appl Health Econ Health Policy. 2015 Feb 4. [Epub ahead of print] PubMed PMID: 25650349.

19: Chandra A, Snider JT, Wu Y, et. al. Robot-assisted surgery for kidney cancer increased access to a procedure that can reduce mortality and renal failure. Health Aff (Millwood). 2015 Feb 1;34(2):220-8. PubMed PMID: 25646101.

20: Okubo R, Kondo M, Hoshi SL, et. al. Cost-effectiveness of obstructive sleep apnea screening for patients with diabetes or chronic kidney disease. Sleep Breath. 2015 Feb 3. [Epub ahead of print] PubMed PMID: 25643768.

21: Borisenko O, Adam D, Funch-Jensen P, et. al. Bariatric Surgery can Lead to Net Cost Savings to Health Care Systems: Results from a Comprehensive European Decision Analytic Model. Obes Surg. 2015 Feb 2. [Epub ahead of print] PubMed PMID: 25639648.

22: Scalone L, Cortesi PA. Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in Italy: the importance of using updated and adequate social tariffs to calculate quality-adjusted life-years. BioDrugs. 2015 Feb;29(1):69. PubMed PMID: 25633571.

23: Kazerooni R, Broadhead C. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia. Am J Health Syst Pharm. 2015 Feb 15;72(4):301-7. PubMed PMID: 25631837.

24: Zachariah JP, Samnaliev M. Echo-based screening of rheumatic heart disease in children: a cost-effectiveness Markov model. J Med Econ. 2015 Feb 9:1-10. [Epub ahead of print] PubMed PMID: 25629653.

25: Al Hussein Al Awamlh B, Lee R, Chughtai B, et. al. A Cost-effectiveness Analysis of Management of Low-risk Non-muscle-invasive Bladder Cancer Using Office-based Fulguration. Urology. 2015 Feb;85(2):381-7. PubMed PMID: 25623694.

26: Tanaka E, Inoue E, Hoshi D, et. al. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Mod Rheumatol. 2015 Feb 11:1-11. [Epub ahead of print] PubMed PMID: 25547018.

27: Sawyer LM, Wonderling D, Jackson K, et. al. Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis. Pharmacoeconomics. 2015 Feb;33(2):163-77. PubMed PMID: 25526841.

28: Kongnakorn T, Lanitis T, Annemans L, et. al. Stroke and systemic embolism prevention in patients with atrial fibrillation in belgium: comparative cost effectiveness of new oral anticoagulants and warfarin. Clin Drug Investig. 2015 Feb;35(2):109-19. PubMed PMID: 25511639.

29: Aballéa S, Maman K, Thokagevistk K, et. al. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United kingdom. Clin Drug Investig. 2015 Feb;35(2):83-93. PubMed PMID: 25491433.

30: Nord E. Cost-value analysis of health interventions: introduction and update on methods and preference data. Pharmacoeconomics. 2015 Feb;33(2):89-95. PubMed PMID: 25488879.

31: Sprague BL, Stout NK, Schechter C, et. al. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med. 2015 Feb 3;162(3):157-66. PubMed PMID: 25486550.

32: Rajan S, Baraniuk S, Parker S, et. al. Implementing a mobile stroke unit program in the United States: why, how, and how much? JAMA Neurol. 2015 Feb 1;72(2):229-34. PubMed PMID: 25485723.

33: Blank PR, Filipits M, Dubsky P, et. al. Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. Pharmacoeconomics. 2015 Feb;33(2):179-90. PubMed PMID: 25404424.

34: Hsieh HM, Tsai SL, Shin SJ, et. al. Cost-Effectiveness of Diabetes Pay-for-Performance Incentive Designs. Med Care. 2015 Feb;53(2):106-15. PubMed PMID: 25397966.

35: Huh WK, Williams E, Huang J, et. al. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening. Appl Health Econ Health Policy. 2015 Feb;13(1):95-107. PubMed PMID: 25385310.

36: Ziakas PD, Zacharioudakis IM, Zervou FN, et. al. Methicillin-Resistant Staphylococcus aureus Prevention Strategies in the ICU: A Clinical Decision Analysis*. Crit Care Med. 2015 Feb;43(2):382-93. PubMed PMID: 25377019.

37: McEwan P, Bennett H, Ward T, et. al. Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK. Pharmacoeconomics. 2015 Feb;33(2):149-61. PubMed PMID: 25344660.

38: Greenhalgh J, Bagust A, Boland A, et. al. Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. Pharmacoeconomics. 2015 Feb;33(2):137-48. PubMed PMID: 25213036.

39: Rognoni C, Marchetti M, Quaglini S, et. al. Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. J Thromb Thrombolysis. 2015 Feb;39(2):149-54. PubMed PMID: 24973057.

40: Ma Y, Ying X, Zou H, et. al. Cost-utility Analysis of Rhegmatogenous Retinal Detachment Surgery in Shanghai, China. Ophthalmic Epidemiol. 2015 Feb;22(1):13-9. Epub 2014 Feb 14. PubMed PMID: 24527711.

By CEA Registry Team on 2/6/2015 9:39 AM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Rowland MR, Lesnock JL, Farris C, et. al. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced stage ovarian cancer in patients = 65 years old. Am J Obstet Gynecol. 2015 Jan 30. [Epub ahead of print] PubMed PMID: 25644442.

2: Mash R, Kroukamp R, Gaziano T, et. al. Cost-effectiveness of a diabetes group education program delivered by health promoters with a guiding style in underserved communities in Cape Town, South Africa. Patient Educ Couns. 2015 Jan  20. [Epub ahead of print] PubMed PMID: 25641665.

3: Mailhot Vega R, Kim J, Hollander A, et. al. Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children. Cancer. 2015 Jan 29. [Epub ahead of print] PubMed PMID: 25641407.

4: Schuster A, Faulkner M, Zeymer U, et. al. Economic implications of intra-aortic balloon support for myocardial infarction with cardiogenic shock: an analysis from the IABP-SHOCK II-trial. Clin Res Cardiol. 2015 Jan 31. [Epub ahead of print] PubMed PMID: 25637294.

5: McEwan P, Ward T, Bennett H, et. al. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One. 2015 Jan 30;10(1):e0117334. eCollection 2015. PubMed PMID: 25635922.

6: Black WC. Computed Tomography Screening for Lung Cancer in the National Lung Screening Trial: A Cost-effectiveness Analysis. J Thorac Imaging. 2015 Jan 29. [Epub ahead of print] PubMed PMID: 25635704.

7: Hagberg L, Hermansson L, Fredriksson C, et. al. Cost-effectiveness of powered mobility devices for elderly people with disability. Disabil Rehabil Assist Technol. 2015 Jan 30:1-6. [Epub ahead of print] PubMed PMID: 25634493.

8: Scalone L, Cortesi PA. Cost-Utility Analysis of Biologic Therapies to Treat Chronic Plaque Psoriasis in Italy: The Importance of Using Updated and Adequate Social Tariffs to Calculate Quality-Adjusted Life-Years. BioDrugs. 2015 Jan 30. [Epub ahead of print] PubMed PMID: 25633571.

9: Moran AE, Odden MC, Thanataveerat A, et. al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015 Jan 29;372(5):447-55. PubMed PMID: 25629742.

10: Zachariah JP, Samnaliev M. Echo-based screening of rheumatic heart disease in children: a cost-effectiveness Markov model. J Med Econ. 2015 Jan 28:1-30. [Epub ahead of print] PubMed PMID: 25629653.

11: Roberts KJ, Sutton AJ, Prasad KR, et. al. Cost-utility analysis of operative versus non-operative treatment for colorectal liver metastases. Br J Surg. 2015 Jan 26. [Epub ahead of print] PubMed PMID: 25624168.

12: Palmer R, Cooper C, Enderby P, et. al. Clinical and cost effectiveness of computer treatment for aphasia post stroke (Big CACTUS): study protocol for a randomised controlled trial. Trials. 2015 Jan 27;16(1):18. [Epub ahead of print] PubMed PMID: 25623162.

13: Hunter R. Cost-Effectiveness of Point-of-Care C-Reactive Protein Tests for Respiratory Tract Infection in Primary Care in England. Adv Ther. 2015 Jan;32(1):69-85. Epub 2015 Jan 27. PubMed PMID: 25620538.

14: Younossi ZM, Park H, Saab S, et. al. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015 Jan 26. [Epub ahead of print] PubMed PMID: 25619871.

15: Wade R, Duarte A, Simmonds M, et. al. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence. Pharmacoeconomics. 2015 Jan 24. [Epub ahead of print] PubMed PMID: 25616671.

16: Vanneste BG, Pijls-Johannesma M, Van De Voorde L, et. al. Spacers in radiotherapy treatment of prostate cancer: Is reduction of toxicity cost-effective? Radiother Oncol. 2015 Jan 20. [Epub ahead of print] PubMed PMID: 25616537.

17: Lønne G, Johnsen LG, Aas E, et. al. Comparing cost-effectiveness of X-stop to minimally Invasive Decompression in Lumbar Spinal Stenosis: A Randomized Controlled Trial. Spine (Phila Pa 1976). 2015 Jan 20. [Epub ahead of print] PubMed PMID: 25608246.

18: Tierney WM. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2015 Jan 22;372(4):387-8. PubMed PMID: 25607439.

19: Pinsky PF. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2015 Jan 22;372(4):387. PubMed PMID: 25607438.

20: Black WC, Keeler EB, Soneji SS. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2015 Jan 22;372(4):388. PubMed PMID: 25607437.

21: Haas M, De Abreu Lourenco R. Pharmacological Management of Chronic Lower Back Pain: A Review of Cost Effectiveness. Pharmacoeconomics. 2015 Jan 22. [Epub ahead of print] PubMed PMID: 25604096.

22: Kirsch F. A systematic review of quality and cost-effectiveness derived from Markov models evaluating smoking cessation interventions in patients with chronic obstructive pulmonary disease. Expert Rev Pharmacoecon Outcomes Res. 2015 Jan 20:1-16. [Epub ahead of print] PubMed PMID: 25600470.

23: Whitehurst DG, Bryan S, Lewis M, et. al. Implementing Stratified Primary care Management for low Back Pain: Cost Utility Analysis alongside a Prospective, Population-based, Sequential Comparison Study. Spine (Phila Pa 1976). 2015 Jan 16. [Epub ahead of print] PubMed PMID: 25599287.

24: Hansson E, Ekman I, Swedberg K, et. al. Person-centred care for patients with chronic heart failure - a cost-utility analysis. Eur J Cardiovasc Nurs. 2015 Jan 16. [Epub ahead of print] PubMed PMID: 25595358.

25: Aboagye E, Karlsson ML, Hagberg J, et. al. Cost-effectiveness of early interventions for non-specific low back pain: A randomized controlled study investigating medical yoga, exercise therapy and self-care advice. J Rehabil Med. 2015 Jan 27;47(2):167-73. PubMed PMID: 25403347.

By CEA Registry Team on 1/16/2015 1:32 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Lee BY, Bartsch SM, Brown ST, et. al. Quantifying the Economic Value and Quality of Life Impact of Earlier Influenza Vaccination. Med Care. 2015 Jan 14. [Epub ahead of print] PubMed PMID: 25590676.

2: Romanus D, Cardarella S, Cutler D, et. al. Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small Cell Lung Cancer. J Thorac Oncol. 2015 Jan 14. [Epub ahead of print] PubMed PMID: 25590606.

3: Looker KJ, Wallace LA, Turner KM. Impact and cost-effectiveness of chlamydia testing in Scotland: a mathematical modelling study. Theor Biol Med Model. 2015 Jan 15;12(1):2. [Epub ahead of print] PubMed PMID: 25588390.

4: Stoddart A, van der Pol M, Pinnock H, et. al. Telemonitoring for chronic obstructive pulmonary disease: a cost and cost-utility analysis of a randomised controlled trial. J Telemed Telecare. 2015 Jan 13. [Epub ahead of print] PubMed PMID: 25586810.

5: Huxley N, Jones-Hughes T, Coelho H, et. al. A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer. Health Technol Assess. 2015 Jan;19(2):1-216. PubMed PMID: 25586547.

6: Grosse SD, Chaugule SS, Hay JW. Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res. 2015 Jan 14:1-17. [Epub ahead of print] PubMed PMID: 25585817.

7: Ross EL, Weinstein MC, Schackman BR, et. al. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clin Infect Dis. 2015 Jan 12. [Epub ahead of print] PubMed PMID: 25583979.

8: Wong WW, Tu HA, Feld JJ, et. al. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ. 2015 Jan 12. [Epub ahead of print] PubMed PMID: 25583667.

9: Quartuccio L, Di Bidino R, Ruggeri M, et. al. Cost-effectiveness analysis of two Rituximab retreatment regimens for longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015 Jan 7. [Epub ahead of print] PubMed PMID: 25581074.

10: Gaudette É, Goldman DP, Messali A, et. al. Do Statins Reduce the Health and Health Care Costs of Obesity? Pharmacoeconomics. 2015 Jan 10. [Epub ahead of print] PubMed PMID: 25576147.

11: Kvamme MK, Lie E, Uhlig T, et. al. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies. Rheumatology (Oxford). 2015 Jan 7. [Epub ahead of print] PubMed PMID: 25573840.

12: Ang M, Nguyen HV, Kiew SY, et. al. Cost-effectiveness of alternative strategies for interferon-γ release assays and tuberculin skin test in tuberculous uveitis. Br J Ophthalmol. 2015 Jan 8. [Epub ahead of print] PubMed PMID: 25573149.

13: You JH, Lui G, Kam KM, et. al. Cost-effectiveness analysis of the Xpert MTB/RIF assay for rapid diagnosis of suspected tuberculosis in an intermediate burden area. J Infect. 2015 Jan 6. [Epub ahead of print] PubMed PMID: 25573001.

14: Zhang Z, Kolm P, Grau-Sepulveda MV, et. al. Cost-Effectiveness of Revascularization Strategies: The ASCERT Study. J Am Coll Cardiol. 2015 Jan 6;65(1):1-11. PubMed PMID: 25572503.

15: Stollenwerk B, Bartmus T, Klug F, et. al. Cost-effectiveness of hip protector use on a geriatric ward in Germany: a Markov model. Osteoporos Int.2015 Jan 9. [Epub ahead of print] PubMed PMID: 25572047.

16: Dick AW, Perencevich EN, Pogorzelska-Maziarz M, et. al. A decade of investment in infection prevention: A cost-effectiveness analysis. Am J Infect Control. 2015 Jan 1;43(1):4-9. PubMed PMID: 25564117.

17: Obreli-Neto PR, Marusic S, Guidoni CM, et. al. Economic evaluation of a pharmaceutical care program for elderly diabetic and hypertensive patients in primary health care: a 36-month randomized controlled clinical trial. J Manag Care Spec Pharm. 2015 Jan;21(1):66-75. PubMed PMID: 25562774.

18: Delea TE, Amdahl J, Diaz J, et. al. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. J Manag Care Spec Pharm. 2015 Jan;21(1):46-54. PubMed PMID: 25562772.

19: Chen LA, Kim J, Boucher K, et. al. Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers. Gynecol Oncol. 2015 Jan 3. [Epub ahead of print] PubMed PMID: 25562668.

20: Shearer DW, Youm J, Bozic KJ. Short-term Complications Have More Effect on Cost-effectiveness of THA than Implant Longevity. Clin Orthop Relat Res. 2015 Jan 6. [Epub ahead of print] PubMed PMID: 25560958.

21: Minor T, Lasher A, Klontz K, et. al. The Per Case and Total Annual Costs of Foodborne Illness in the United States. Risk Anal. 2015 Jan 2. [Epub ahead of print] PubMed PMID: 25557397.

22: Hendriksen JM, Geersing GJ, van Voorthuizen SC, et. al. The cost-effectiveness of point-of-care D-dimer tests compared with a laboratory test to rule out deep venous thrombosis in primary care. Expert Rev Mol Diagn. 2015 Jan;15(1):125-36. PubMed PMID: 25537569.

23: D'Amico F, Rehill A, Knapp M, et. al. Maintenance cognitive stimulation therapy: an economic evaluation within a randomized controlled trial. J Am Med Dir Assoc. 2015 Jan 1;16(1):63-70. PubMed PMID: 25528281.

24: Gupta V, Baabbad R, Hammerby E, et. al. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes. J Med Econ. 2015 Jan 2:1-10. [Epub ahead of print] PubMed PMID: 25426701.

25: Revill PA, Walker S, Mabugu T, et. al. Opportunities for improving the efficiency of paediatric HIV treatment programmes. AIDS. 2015 Jan 14;29(2):201-10. PubMed PMID: 25396263.

26: Rochau U, Sroczynski G, Wolf D, et. al. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leuk Lymphoma. 2015 Jan 14:1-11. [Epub ahead of print] PubMed PMID: 25393806.

27: Schackman BR, Leff JA, Barter DM, et. al. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction. 2015 Jan;110(1):129-43. PubMed PMID: 25291977.

28: Beresniak A, Medina-Lara A, Auray JP, et. al. Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results from the ECHOUTCOME European Project. Pharmacoeconomics. 2015 Jan;33(1):61-9. PubMed PMID: 25230587.

29: Yu SY, Lee TJ, Jang SH, et. al. Cost-effectiveness of nationwide opportunistic screening program for dementia in South Korea. J Alzheimers Dis. 2015 Jan 1;44(1):195-204. PubMed PMID: 25208621.

30: Fleeman N, Bagust A, Beale S, et. al. Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. Pharmacoeconomics. 2015 Jan;33(1):13-23. PubMed PMID: 25138171.

31: King CH. Health metrics for helminth infections. Acta Trop. 2015 Jan;141(PtB):150-60. Epub 2013 Dec 12. PubMed PMID: 24333545.

By CEA Registry Team on 1/5/2015 1:13 PM

By Peter Neumann, Sc.D. and Cayla Saret, B.A.

Cost-effectiveness thresholds, healthcare spending, quality-adjusted life years (QALYs)…we covered these topics and more in 2014. Here are some of our most popular posts of the past year. Follow us on Twitter and Facebook for updates.

1.       FDA considers draft guidance on FDAMA Section 114 (March 11): The Food and Drug Administration may offer further guidance on legislation that governs pharmaceutical companies’ promotion of health economic information.

2.       The curious resilience of the $50,000-per-QALY threshold (Aug 27): Researchers argue that multiple cost-effectiveness thresholds should replace the outdated $50,000-per-QALY metric.

3.       Cost-effectiveness analysis of personalized medicine: How much uncertainty is acceptable?: (Feb 27): Researchers debate the use of cost-effectiveness analysis for new genetic tests that may lack firm evidence of clinical effectiveness.

4.       Do specialty drugs offer value for money? (Oct 6): Specialty drugs may, in many cases, offer good value despite higher costs.

5.       Photo highlights from the CEVR symposium and celebratory dinner (Sept 22): In September, CEVR held a Symposium on Innovation and Cost-Effectiveness Research and a dinner to celebrate the CEA Registry’s 15th Anniversary.

6.       What are the returns of cancer research? Using QALYs to calculate IRR (Jul 16): One of the few papers to qualify the overall returns of medical research suggests “substantial” return for development of cancer-related interventions.

7.       Do PBM’s recent formulary restrictions point to an increased role for cost-effectiveness analysis in the US? (Aug 5): Changes in coverage policy by Express Scripts and CVS Caremark suggest that cost-effectiveness analysis may play a greater role in decisions by U.S. payers.

8.       Why the spike in new cost utility analyses in 2012? (March 27): Two possible explanations may illuminate why about 45% more cost-utility analyses were published in 2012 than 2011.

9.       What cost-effectiveness thresholds do US health economics cite most often? (Aug 28): While the $50,000-per-QALY threshold is commonly used, use of the $100,000-per-QALY benchmark is also increasing.

10.   A half century of US healthcare spending (Jul 24): A report by the California HealthCare Foundation provided insight into changes in healthcare spending in the last 50 years.

 

By CEA Registry Team on 1/5/2015 11:43 AM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Wen F, Yao K, Du ZD, et. al. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials. World J Gastroenterol. 2014 Dec 21;20(47):17976-84. PubMed PMID: 25548497.

2: Brettschneider C, Djadran H, Härter M, et. al. Cost-Utility Analyses of Cognitive-Behavioural Therapy of Depression: A Systematic Review. Psychother Psychosom. 2014 Dec 24;84(1):6-21. [Epub ahead of print] PubMed PMID: 25547334.

3: Tanaka E, Inoue E, Hoshi D, et. al. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Mod Rheumatol.2014 Dec 30:1-31. [Epub ahead of print] PubMed PMID: 25547018.

4: Domínguez-Ortega J, Phillips-Anglés E, Barranco P, et. al. Cost-effectiveness of asthma therapy: A Comprehensive review. J Asthma. 2014 Dec 24:1-23. [Epub ahead of print] PubMed PMID: 25539023.

5: Huang YA, Lasry A, Hutchinson AB, et. al. A Systematic Review on Cost Effectiveness of HIV Prevention Interventions in the United States. Appl Health Econ Health Policy. 2014 Dec 25. [Epub ahead of print] PubMed PMID: 25536927.

6: Crespo C, Monleon A, Díaz W, et. al. Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies. BMC Med Res Methodol. 2014 Dec 22;14(1):139. [Epub ahead of print] PubMed PMID: 25533141.

7: Gouveia M, Borges M, Trindade R, et. al. Economic evaluation of ticagrelor for secondary prevention following acute coronary syndromes. Rev Port Cardiol. 2014 Dec 16. [Epub ahead of print] English, Portuguese. PubMed PMID: 25528973.

8: Shiragami M, Mizukami A, Leeuwenkamp O, et. al. Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children. Infect Dis Ther. 2014 Dec 20. [Epub ahead of print] PubMed PMID: 25527448.

9: Hamid R, Loveman C, Millen J, et. al. Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX(®)) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective. Pharmacoeconomics. 2014 Dec 20. [Epub ahead of print] PubMed PMID: 25526842.

10: Sawyer LM, Wonderling D, Jackson K, et. al. Biological Therapies for the Treatment of Severe Psoriasis in Patients with Previous Exposure to Biological Therapy: A Cost-Effectiveness Analysis. Pharmacoeconomics. 2014 Dec 20. [Epub ahead of print] PubMed PMID: 25526841.

11: Wu B, Li T, Cai J, et. al. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer. 2014 Dec 19;14(1):984. PubMed PMID: 25526802.

12: Farag I, Howard K, Ferreira ML, et. al. Economic modelling of a public health programme for fall prevention. Age Ageing. 2014 Dec 18. [Epub ahead of print] PubMed PMID: 25523025.

13: Hole AR, Norman R, Viney R. RESPONSE PATTERNS IN HEALTH STATE VALUATION USING ENDOGENOUS ATTRIBUTE ATTENDANCE AND LATENT CLASS ANALYSIS. Health Econ. 2014 Dec 17. [Epub ahead of print] PubMed PMID: 25521533.

14: Kawasaki R, Akune Y, Hiratsuka Y, et. al. Cost-utility Analysis of Screening for Diabetic Retinopathy in Japan: A Probabilistic Markov Modeling Study. Ophthalmic Epidemiol. 2014 Dec 17:1-9. [Epub ahead of print] PubMed PMID: 25517603.

15: Offodile AC 2nd, Chatterjee A, Vallejo S, et. al. A Cost-Utility Analysis of the Use of Preoperative Computed Tomographic-Angiography in Abdomen-Based Perforator Flap Breast Reconstruction. Plast Reconstr Surg. 2014 Dec 16. [Epub ahead of print] PubMed PMID: 25517410.

16: Janzic A, Kos M. Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control. Pharmacoeconomics. 2014 Dec 16. [Epub ahead of print] PubMed PMID: 25512096.

17: Kongnakorn T, Lanitis T, Annemans L, et. al. Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin. Clin Drug Investig. 2014 Dec 16. [Epub ahead of print] PubMed PMID: 25511639.

By CEA Registry Team on 12/16/2014 1:25 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Ladabaum U, Mannalithara A, Jandorf L, et. al. Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals. Cancer. 2014 Dec 9. [Epub ahead of print] PubMed PMID: 25492455.

2: Aballéa S, Maman K, Thokagevistk K, et. al. Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom. Clin Drug Investig. 2014 Dec 10. [Epub ahead of print] PubMed PMID:25491433.

3: Nichols BE, Sigaloff KC, Kityo C, et. al. Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study. J Int AIDS Soc. 2014 Dec 5;17(1):19164. eCollection 2014. PubMed PMID: 25491351.

4: Delea TE, Amdahl J, Nakhaipour HR, et. al. Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada. Curr Oncol. 2014 Dec;21(6):e748-59. PubMed PMID: 25489263.

5: Delea TE, Amdahl J, Wang A, et. al. Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada. Pharmacoeconomics. 2014 Dec 9. [Epub ahead of print] PubMed PMID: 25488880.

6: de Almeida JR, Moskowitz AJ, Miles BA, et. al. Transoral robotic surgery is cost-effective compared to (Chemo)radiotherapy for early t-classification oropharyngeal carcinoma: A cost-utility analysis. Head Neck. 2014 Dec 9. [Epub ahead of print] PubMed PMID: 25488048.

7: Sprague BL, Stout NK, Schechter C, et. al. Benefits, Harms, and Cost-Effectiveness of Supplemental Ultrasonography Screening for Women With Dense Breasts. Ann Intern Med. 2014 Dec 9. [Epub ahead of print] PubMed PMID: 25486550.

8: Rajan S, Baraniuk S, Parker S, et. al. Implementing a Mobile Stroke Unit Program in the United States: Why, How, and How Much? JAMA Neurol. 2014 Dec 8. [Epub ahead of print] PubMed PMID: 25485723.

9: Roze S, Saunders R, Brandt AS, et. al. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes. Diabet Med. 2014 Dec 6. [Epub ahead of print] PubMed PMID: 25483869.

10: Ebm CC, Sutton L, Rhodes A, et. al. Cost-Effectiveness in Goal-Directed Therapy: Are the Dollars Spent Worth the Value? J Cardiothorac Vasc Anesth. 2014 Dec;28(6):1660-1666. Review. PubMed PMID: 25479922.

11: McCann GA, Cohn DE, Jewell EL, et. al. Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis. Gynecol Oncol. 2014 Dec 2. [Epub ahead of print] PubMed PMID: 25478927.

12: Fletcher JJ, Kotagal V, Mammoser A, et. al. Cost-Effectiveness of Transfers to Centers With Neurological Intensive Care Units After Intracerebral Hemorrhage. Stroke. 2014 Dec 4. [Epub ahead of print] PubMed PMID: 25477220.

13: Zhang W, Islam N, Ma C, et. al. Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis. Pharmacoeconomics. 2014 Dec 5. [Epub ahead  of print] PubMed PMID: 25475964.

14: Raizer JJ, Fitzner KA, Jacobs DI, et. al. Economics of Malignant Gliomas: A Critical Review. J Oncol Pract. 2014 Dec 2. [Epub ahead of print] PubMed PMID: 25466707.

15: Mather RC 3rd, Garrett WE, Cole BJ, et. al. Cost-effectiveness Analysis of the Diagnosis of Meniscus Tears. Am J Sports Med. 2014 Dec 1. [Epub ahead of print] PubMed PMID: 25451791.

16: Dilla T, Möller J, O Donohoe P, et. al. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain: a cost-effectiveness comparison. BMC Psychiatry. 2014 Dec 2;14(1):298. [Epub ahead of print] PubMed PMID: 25438678.

17: Wu B, Song Y, Leng L, et. al. Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars. Clin Exp Rheumatol. 2014 Dec 1. [Epub ahead of print] PubMed PMID: 25438197.

18: Mowatt G, Hernández R, Castillo M, et. al. Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess. 2014 Dec;18(69):1-254. PubMed PMID: 25436855.

19: Weinstein JN, Tosteson AN, Tosteson TD, et. al. The SPORT Value Compass: Do the Extra Costs of Undergoing Spine Surgery Produce Better Health Benefits? Med Care. 2014 Dec;52(12):1055-63. PubMed PMID: 25334052.

20: Verhoef TI, Redekop WK, Hasrat F, et. al. Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. Am J Cardiovasc Drugs. 2014 Dec;14(6):451-62. PubMed PMID: 25326294.

21: Rizzi CF, Ferraz MB, Poyares D, et. al. Quality-Adjusted Life-Years Gain and Health Status in Patients with OSAS after One Year of Continuous Positive Airway  Pressure Use. Sleep. 2014 Dec 1;37(12):1963-8. PubMed PMID: 25325505.

22: Wang Y, Xie F, Kong MC, et. al. Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation. Cardiovasc Drugs Ther. 2014 Dec;28(6):575-85. PubMed PMID: 25319314.

23: Lewis DJ, Attiah MA, Malhotra NR, Burnett MG, Stein SC. Anterior Surgical Management of Single-Level Cervical Disc Disease: A Cost-effectiveness Analysis. Spine (Phila Pa 1976). 2014 Dec 1;39(25):2084-92. PubMed PMID: 25271510.

24: Chung O, Vongpatanasin W, Bonaventura K, Lotan Y, Sohns C, Haverkamp W, Dorenkamp M. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens. 2014 Dec;32(12):2411-21. PubMed PMID: 25255395.

25: Thoma A, Kaur MN, Tsoi B, Ziolkowski N, Duku E, Goldsmith CH. Cost-effectiveness analysis parallel to a randomized controlled trial comparing vertical scar reduction and inverted T-shaped reduction mammaplasty. Plast Reconstr Surg. 2014 Dec;134(6):1093-107. PubMed PMID: 25255113.

26: Alberts SR, Yu TM, Behrens RJ, Renfro LA, Srivastava G, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim GP, Mazurczak MA, Hornberger J. Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer. Pharmacoeconomics. 2014 Dec;32(12):1231-43. PubMed PMID: 25154747.

27: Vellopoulou A, van Agthoven M, van der Kolk A, de Knegt RJ, Berdeaux G, Cure S, Bianic F, Lamotte M. Cost Utility of Telaprevir-PR (Peginterferon-Ribavirin) Versus Boceprevir-PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands. Appl Health Econ Health Policy. 2014 Dec;12(6):647-59. PubMed PMID: 25103219.

28: Gladwell D, Henry T, Cook M, Akehurst R. Cost Effectiveness of Renal Denervation Therapy for the Treatment of Resistant Hypertension in the UK. Appl Health Econ Health Policy. 2014 Dec;12(6):611-22. PubMed PMID: 25086585.

29: Messali A, Villacorta R, Hay JW. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics. 2014 Dec;32(12):1201-12. PubMed PMID: 25085219.

30: Castilla I, Mar J, Valcárcel-Nazco C, Arrospide A, Ramos-Goñi JM. Cost-utility analysis of gastric bypass for severely obese patients in Spain. Obes Surg. 2014 Dec;24(12):2061-8. PubMed PMID: 24913241.

By CEA Registry Team on 11/17/2014 4:45 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Hsieh HM, Tsai SL, Shin SJ, et. al. Cost-Effectiveness of Diabetes Pay-for-Performance Incentive Designs. Med Care. 2014 Nov 13. [Epub ahead of print] PubMed PMID: 25397966.

2: Sax PE, Sypek A, Berkowitz BK, et. al. HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy? PLoS One. 2014 Nov 14;9(11):e113031. eCollection 2014. PubMed PMID: 25397616.

3: Maggiolo F, Di Matteo S, Bruno G, et. al. Switching from an EFV-based STR to a RPV-based STR is effective, safe and improves HIV patients health status. J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19798.eCollection 2014. PubMed PMID: 25397542.

4: Revill PA, Walker S, Mabugu T, et. al. Opportunities for improving the efficiency of paediatric HIV treatment programmes: lessons from the ARROW trial. AIDS. 2014 Nov 13. [Epub ahead of print] PubMed PMID: 25396263.

5: Petrou S, Boland A, Khan K, et. al. ECONOMIC EVALUATION OF NEBULIZED MAGNESIUM SULPHATE IN ACUTE SEVERE ASTHMA IN CHILDREN. Int J Technol Assess Health Care. 2014 Nov 14:1-7. [Epub ahead of print] PubMed PMID: 25394502.

6: Bennette CS, Gallego CJ, Burke W, et. al. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genet Med. 2014 Nov 13. [Epub ahead of print] PubMed PMID: 25394171.

7: Peng S, Tafazzoli A, Dorman E, et. al. Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19605.  eCollection 2014. PubMed PMID: 25394109.

8: Oddershede L, Walker S, Paton N, et. al. Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19498. eCollection 2014. PubMed PMID: 25394007.

9: Rochau U, Sroczynski G, Wolf D, et. al. Cost-Effectiveness of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Leuk Lymphoma. 2014 Nov 13:1-40. [Epub ahead of print] PubMed PMID: 25393806.

10: Reynolds MR, Apruzzese P, Galper BZ, et. al. Cost-Effectiveness of Supervised Exercise, Stenting, and Optimal Medical Care for Claudication: Results From the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Trial. J Am Heart Assoc. 2014 Nov 11;3(6). PubMed PMID: 25389284.

11: Huh WK, Williams E, Huang J, et. al. Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening. Appl Health Econ Health Policy. 2014 Nov 11. [Epub ahead of print] PubMed PMID: 25385310.

12: Borgström F, Beall DP, Berven S, et. al. Health economic aspects of vertebral augmentation procedures. Osteoporos Int. 2014 Nov 8. [Epub ahead of print] PubMed PMID: 25381046.

13: Lehnert T, Streltchenia P, Konnopka A, et. al. Health burden and costs of obesity and overweight in Germany: an update. Eur J Health Econ. 2014 Nov 8. [Epub ahead of print] PubMed PMID: 25381038.

14: Sørensen J, Primdahl J, Horn H, et. al. Shared care or nurse consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis (RA) outpatients with stable low disease-activity RA: cost-effectiveness based on a 2-year randomized trial. Scand J Rheumatol. 2014 Nov 7:1-9. [Epub ahead of print] PubMed PMID: 25380077.

15: Ziakas PD, Zacharioudakis IM, Zervou FN, et. al. Methicillin-Resistant Staphylococcus aureus Prevention Strategies in the ICU: A Clinical Decision Analysis. Crit Care Med. 2014 Nov 5. [Epub ahead of print] PubMed PMID: 25377019.

16: Black WC, Gareen IF, Soneji SS, et. al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014 Nov 6;371(19):1793-802. PubMed PMID: 25372087.

17: Wright D, Twigg M, Thornley T. Chronic obstructive pulmonary disease case finding by community pharmacists: a potential cost-effective public health intervention. Int J Pharm Pract. 2014 Nov 5. [Epub ahead of print] PubMed PMID: 25371146.

18: Henry TL, De Brouwer BF, Van Keep MM, et. al. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands. J Med Econ. 2014 Nov 7:1-12. [Epub ahead of print] PubMed PMID: 25367314.

19: Varier RU, Biltaji E, Smith KJ, et. al. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection. Clin Microbiol Infect. 2014 Nov 3. [Epub ahead of print] PubMed PMID: 25366338.

20: Jutkowitz E, Choi HK, Pizzi LT, et. al. Cost-effectiveness of allopurinol and febuxostat for the management of gout. Ann Intern Med. 2014 Nov 4;161(9):617-26. doi: 10.7326/M14-0227. PubMed PMID: 25364883.

21: Olgiati P, Bajo E, Serretti A; C.E.A.P (Cost-Effectiveness Analysis on Psychiatric Disorders) - group. Benefit of slow titration of paroxetine to treat  depression in the elderly. Hum Psychopharmacol. 2014 Nov;29(6):544-51. Epub 2014 Nov 3. PubMed PMID: 25363240.

22: Cangelosi MJ, Ortendahl JD, Meckley LM, et. al. Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma. Expert Rev Pharmacoecon Outcomes Res. 2014 Nov 1:1-8. [Epub ahead of print] PubMed PMID: 25363000.

23: Lewis MA, Bann CM, Karns SA, et. al. Cross-site evaluation of the alliance to reduce disparities in diabetes: clinical and patient-reported outcomes. Health Promot Pract. 2014 Nov;15(2 Suppl):92S-102S. PubMed PMID: 25359255.

24: Bae YH, Mullins CD. Do value thresholds for oncology drugs differ from nononcology drugs? J Manag Care Pharm. 2014 Nov;20(11):1086-92. PubMed PMID: 25351969.

25: Palmieri V, Baldi C, Di Blasi PE, et. al. Impact of DRG billing system on health budget consumption in percutaneous treatment of mitral valve regurgitation in heart failure. J Med Econ. 2014 Nov 4:1-7. [Epub ahead of print] PubMed PMID: 25350644.

26: Walter E, Odin P. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany. J Med Econ. 2014 Nov 11:1-11. [Epub ahead of print] PubMed PMID: 25348011.

27: Attard CL, Pepper AN, Brown ST, et. al. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. J Med Econ. 2014 Nov 10:1-16. [Epub ahead of print] PubMed PMID: 25347449.

28: Claxton L, Malcolm B, Taylor M, et. al. Ranibizumab, Verteporfin  Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK. Drugs Aging. 2014 Nov;31(11):837-48. PubMed PMID: 25300507; PubMed Central PMCID: PMC4210643.

29: Tassie E, Scotland G, Brittenden J, et. al. Cost-effectiveness of ultrasound-guided foam sclerotherapy, endovenous laser ablation or surgery as treatment for primary varicose veins from the randomized CLASS trial. Br J Surg. 2014 Nov;101(12):1532-40. PubMed PMID: 25274220.

30: Negrón ME, Kaplan GG, Barkema HW, et. al. Colorectal cancer surveillance in patients with inflammatory bowel disease and primary sclerosing cholangitis: an economic evaluation. Inflamm Bowel Dis. 2014 Nov;20(11):2046-55.PubMed PMID: 25230162.

31: McAnany SJ, Overley S, Baird EO, et. al. The 5-Year Cost-effectiveness of Anterior Cervical Discectomy and Fusion and Cervical Disc Replacement: A Markov Analysis. Spine (Phila Pa 1976). 2014 Nov 1;39(23):1924-33. PubMed PMID: 25188602.

32: Paulden M, O'Mahony JF, Culyer AJ, et. al. Some Inconsistencies in NICE's Consideration of Social Values. Pharmacoeconomics. 2014 Nov;32(11):1043-53. PubMed PMID: 25145802.

33: Zueger PM, Schultz NM, Lee TA. Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review. Pharmacoeconomics. 2014 Nov;32(11):1079-91. PubMed PMID: 25052903.

By CEA Registry Team on 11/3/2014 2:22 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Wong FK, So C, Chau J, et. al. Economic evaluation of the differential benefits of home visits with telephone calls and telephone calls only in transitional discharge support. Age Ageing. 2014 Oct 29. [Epub ahead of print] PubMed PMID: 25355620.

2: Lachaine J, Mathurin K, Barakat S, et. al. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. Eur J Haematol. 2014 Oct 29. [Epub ahead of print] PubMed PMID: 25354894.

3: Vallejo-Torres L, Castilla I, González N, et. al. Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model. Psychol Med. 2014 Oct 30:1-12. [Epub ahead of print] PubMed PMID: 25354790.

4: Brosa M, García Del Muro X, Mora J, et. al. Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct 29:1-10. [Epub ahead of print] PubMed PMID: 25354299.

5: Coward S, Heitman SJ, Clement F, et. al. Funding a Smoking Cessation Program for Crohn's Disease: An Economic Evaluation. Am J Gastroenterol. 2014 Oct 28. [Epub ahead of print] PubMed PMID: 25350768.

6: Palmieri V, Baldi C, Di Blasi PE, et. al. Impact of DRG Billing System on Health Budget Consumption in Percutaneous Treatment of Mitral Valve Regurgitation in Heart Failure. J Med Econ. 2014 Oct 28:1-20. [Epub ahead of print] PubMed PMID: 25350644.

7: Brecker S, Mealing S, Padhiar A, et. al. Cost-utility of transcatheter aortic valve implantation for inoperable patients with severe aortic stenosis treated by medical management: a UK cost-utility analysis based on patient-level data from the ADVANCE study. Open Heart. 2014 Oct 23;1(1):e000155. eCollection 2014. PubMed PMID: 25349700.

8: Levin LA, Husberg M, Sobocinski PD, et. al. A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke. Europace. 2014 Oct 27. [Epub ahead of print] PubMed PMID: 25349228.

9: Mihalopoulos C, Magnus A, Lal A, et. al. Is implementation of the 2013 Australian treatment guidelines for posttraumatic stress disorder cost-effective compared to current practice? A cost-utility analysis using QALYs and DALYs. Aust N Z J Psychiatry. 2014 Oct 27. [Epub ahead of print] PubMed PMID: 25348698.

10: Pietzsch JB, Liu S, Garner AM, et. al. Long-Term Cost-Effectiveness of Upper Airway Stimulation for the Treatment of Obstructive Sleep Apnea: A Model-Based Projection Based on the STAR Trial. Sleep. 2014 Oct 28.[Epub ahead of print] PubMed PMID: 25348126.

11: Walter E, Odin P. Cost-effectiveness of continuous subcutaneous Apomorphine in the treatment of Parkinson´s Disease in the UK and Germany. J Med Econ. 2014 Oct 28:1-36. [Epub ahead of print] PubMed PMID: 25348011.

12: Attard C, Pepper A, Brown S, et. al. Cost-effectiveness Analysis of Neoadjuvant Pertuzumab and Trastuzumab Therapy for Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer in Canada. J Med Econ. 2014 Oct 27:1-38. [Epub ahead of print] PubMed PMID: 25347449.

13: McEwan P, Bennett H, Ward T, et. al. Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK. Pharmacoeconomics. 2014 Oct 26. [Epub ahead of print] PubMed PMID: 25344660.

14: Trenaman L, Sadatsafavi M, Almeida F, et. al. Exploring the Potential Cost-Effectiveness of Patient Decision Aids for Use in Adults with Obstructive Sleep Apnea: A Case Study. Med Decis Making. 2014 Oct 24. [Epub ahead of print] PubMed PMID: 25344130.

15: Peels DA, Hoogenveen RR, Feenstra TL, et. al. Long-term health outcomes and cost-effectiveness of a computer-tailored physical activity intervention among people aged over fifty: modelling the results of a randomized controlled trial. BMC Public Health. 2014 Oct 23;14(1):1099. [Epub ahead of print] PubMed PMID: 25342517.

16: Aronsson M, Walfridsson H, Janzon M, et. al. The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy. Europace. 2014 Oct 23. [Epub ahead of print] PubMed PMID: 25341739.

17: Oppong R, Jowett S, Nicholls E, et. al. Joint protection and hand exercises for hand osteoarthritis: an economic evaluation comparing methods for the analysis of factorial trials. Rheumatology (Oxford). 2014 Oct 21. [Epub ahead of print] PubMed PMID: 25339642.

18: Shepard DS, Halasa YA, Fonseca DM, et. al. Economic evaluation of an area-wide integrated pest management program to control the asian tiger mosquito in new jersey. PLoS One. 2014 Oct 22;9(10):e111014. eCollection 2014. PubMed PMID: 25338065.

19: Kalra VB, Wu X, Forman HP, et. al. Cost-Effectiveness of Angiographic Imaging in Isolated Perimesencephalic Subarachnoid Hemorrhage. Stroke. 2014 Oct 21. [Epub ahead of print] PubMed PMID: 25336513.

20: Weinstein JN, Tosteson AN, Tosteson TD, et. al. The SPORT Value Compass: Do the Extra Costs of Undergoing Spine Surgery Produce Better Health Benefits? Med Care. 2014 Oct 20. [Epub ahead of print] PubMed PMID: 25334052.

21: Huang H, Taylor DC, Carson RT, et. al. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States. J Med Econ. 2014 Oct 21:1-31. [Epub ahead of print] PubMed PMID: 25333331.

22: You J. Antimicrobial stewardship programs - cost-minimizing or cost-effective? Expert Opin Pharmacother. 2014 Oct 21:1-3. [Epub ahead of print] PubMed PMID: 25331093.

23: Ising HK, Smit F, Veling W, et. al. Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial. Psychol Med. 2014 Oct 21:1-12. [Epub ahead of print] PubMed PMID: 25330734.

24: Ma Y, Ying X, Zou H, et. al. Rhegmatogenous Retinal Detachment Surgery in Elderly People over 70 Years Old: Visual Acuity, Quality of Life, and Cost-Utility Values. PLoS One. 2014 Oct 17;9(10):e110256. eCollection 2014. PubMed PMID: 25330168.

25: Pan Y, Chen Q, Zhao X, et. al.; TIMS-CHINA investigators. Cost-Effectiveness of Thrombolysis within 4.5 Hours of Acute Ischemic Stroke in China. PLoS One. 2014 Oct 20;9(10):e110525. eCollection 2014. PubMed PMID: 25329637.

26: Liu S, Watcha D, Holodniy M, et. al. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in u.s. Incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014 Oct 21;161(8):546-53. PubMed PMID: 25329202.

27: Fortney JC, Pyne JM, Burgess JF Jr. Population-Level Cost-Effectiveness of Implementing Evidence-Based Practices into Routine Care. Health Serv Res. 2014 Oct 18. [Epub ahead of print] PubMed PMID: 25328029.

28: Lerdkiattikorn P, Chaikledkaew U, Lausoontornsiri W, et. al. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct 18:1-14. [Epub ahead of print] PubMed PMID: 25327502.

By CEA Registry Team on 10/16/2014 1:25 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Westwood M, van Asselt T, Ramaekers B, et. al. KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014 Oct;18(62):1-132. PubMed PMID: 25314637.

2: Gong CL, Hay JW. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. J Natl Compr Canc Netw. 2014 Oct;12(10):1417-25. PubMed PMID: 25313181.

3: San Miguel R, Gimeno-Ballester V, Blázquez A, et. al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut. 2014 Oct 13. [Epub ahead of print] PubMed PMID: 25311032.

4: Stanczyk NE, Smit ES, Schulz DN, et. al. An economic evaluation of a video- and text-based computer-tailored intervention for smoking cessation: a cost-effectiveness and cost-utility analysis of a randomized controlled trial. PLoS One. 2014 Oct 13;9(10):e110117.eCollection 2014. PubMed PMID: 25310007.

5: Lamb SE, Williamson EM, Heine PJ, et. al. Exercises to improve function of the rheumatoid hand (SARAH): a randomised controlled trial. Lancet. 2014 Oct 9. [Epub ahead of print] PubMed PMID: 25308290.

6: Price D, Keininger D, Costa-Scharplatz M, et. al. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respir Med. 2014 Oct 2. [Epub ahead of print] PubMed PMID: 25307414.

7: Christensen H, Trotter CL, Hickman M, et. al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014 Oct 9;349:g5725. PubMed PMID: 25301037.

8: Claxton L, Malcolm B, Taylor M, et. al. Ranibizumab, Verteporfin Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK. Drugs Aging. 2014 Oct 10. [Epub ahead of print] PubMed PMID: 25300507.

9: Livingston G, Barber J, Rapaport P, et. al. START (STrAtegies for RelaTives) study: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manual-based coping strategy programme in promoting the mental health of carers of people with dementia. Health Technol Assess. 2014 Oct;18(61):1-242. PubMed PMID: 25300037.

10: Liu JY, You RX, Guo M, et. al. Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation. Am J Ther. 2014 Oct 8. [Epub ahead of print] PubMed PMID: 25299636.

11: Hsu WK, Hashimoto RE, Berven SH, et. al. Biological Substitutes/Extenders for Spinal Arthrodesis: Which Agents Are Cost-effective? Spine (Phila Pa 1976). 2014 Oct 15;39(22 Suppl 1):S86-98. PubMed PMID: 25299264.

12: Harrop JS, Hilibrand A, Mihalovich KE, et. al. Cost-effectiveness of Surgical Treatment for Degenerative Spondylolisthesis and Spinal Stenosis. Spine (Phila Pa 1976). 2014 Oct 15;39(22 Suppl 1):S75-85. PubMed PMID: 25299263.

13: Yan X, Hu HT, Liu S, et. al. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China. Neurol Res. 2014 Oct 8:1743132814Y0000000447. [Epub ahead of print] PubMed PMID: 25297471.

14: Schackman BR, Leff JA, Barter DM, et. al. Cost-effectiveness of rapid HCV testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction. 2014 Oct 8. [Epub ahead of print] PubMed PMID: 25291977.

15: Chambers JD, Thorat T, Pyo J, et. al. Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Aff (Millwood). 2014 Oct 1;33(10):1751-60. PubMed PMID: 25288419.

16: Bonastre J, Marguet S, Lueza B, et. al. Cost Effectiveness of Molecular Profiling for Adjuvant Decision Making in Patients With Node-Negative Breast Cancer. J Clin Oncol. 2014 Oct 6. [Epub ahead of print] PubMed PMID: 25287824.

17: Chen A, Dowdy DW. Clinical Effectiveness and Cost-Effectiveness of HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men: Risk Calculators for Real-World Decision-Making. PLoS One. 2014 Oct 6;9(10):e108742. eCollection 2014. PubMed PMID: 25285793.

18: Swart E, Makhni EC, Macaulay W, et. al. Cost-effectiveness analysis of fixation options for intertrochanteric hip fractures. J Bone Joint Surg Am. 2014 Oct 1;96(19):1612-20. PubMed PMID: 25274786.

19: Evans M, Wolden M, Gundgaard J, et. al. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ. 2014 Oct 1:1-34. [Epub ahead of print] PubMed PMID: 25271378.

20: Lundqvist C, Beiske AG, Reiertsen O, et. al. Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients. J Neurol. 2014 Oct 1. [Epub ahead of print] PubMed PMID: 25270681.

21: Luciano JV, D Amico F, Cerdà-Lafont M, et. al. Cost-utility of cognitive behavioural therapy versus U.S. food and drug administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomised controlled trial. Arthritis Res Ther. 2014 Oct 1;16(5):451. [Epub ahead of print] PubMed PMID: 25270426.

22: Lee WS, Parks NA, Garcia A, et. al. Pan computed tomography versus selective computed tomography in stable, young adults after blunt trauma with moderate mechanism: A cost-utility analysis. J Trauma Acute Care Surg. 2014 Oct;77(4):527-33. PubMed PMID: 25250590.

23: Kongnakorn T, Lanitis T, Annemans L, et. al. Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in belgium. Clin Drug Investig. 2014 Oct;34(10):709-21. PubMed PMID: 25164005.

24: van Hees F, Zauber AG, Klabunde CN, et. al. The appropriateness of more intensive colonoscopy screening than recommended in medicare beneficiaries: a modeling study. JAMA Intern Med. 2014 Oct 1;174(10):1568-76. PubMed PMID: 25133641.

25: Alali AS, Naimark DM, Wilson JR, et. al. Economic evaluation of decompressive craniectomy versus barbiturate coma for refractory intracranial hypertension following traumatic brain injury*. Crit Care Med. 2014 Oct;42(10):2235-43. PubMed PMID: 25054675.

26: Tran-Duy A, Boonen A, Kievit W, et. al. Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis. Pharmacoeconomics. 2014 Oct;32(10):1015-28. PubMed PMID: 24972589.

27: Lairson DR, Parikh RC, Cormier JN, et. al. Cost-Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon Cancer. Pharmacoeconomics. 2014 Oct;32(10):1005-13. PubMed PMID: 24920195.

28: Zafari Z, Thorlund K, FitzGerald JM, et. al. Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes. Pharmacoeconomics. 2014 Oct;32(10):995-1004. PubMed PMID: 24920194.

29: Refaat T, Choi M, Gaber G, et. al. Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer. Am J Clin Oncol. 2014 Oct;37(5):480-5. PubMed PMID: 23388565.

By CEA Registry Team on 10/1/2014 3:17 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Malhotra AK, Goldberg SR, McLay L, et. al. DVT Surveillance Program in the ICU: Analysis of Cost-Effectiveness. PLoS One. 2014 Sep 30;9(9):e106793. eCollection 2014. PubMed PMID: 25269021.

2: Jarungsuccess S, Taerakun S. Cost-Utility Analysis of Oral Anticoagulants for Nonvalvular Atrial Fibrillation Patients at the Police General Hospital, Bangkok, Thailand. Clin Ther. 2014 Sep 27. [Epub ahead of print] PubMed PMID: 25267360.

3: Marchetti M, Liberato NL. Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses. Expert Rev Pharmacoecon Outcomes Res. 2014 Sep 27:1-10. [Epub ahead of print] PubMed PMID: 25262931.

4: Golsteijn R, Peels DA, Evers S, et. al. Cost-effectiveness and cost-utility of a Web-based or print-delivered tailored intervention to promote physical activity among adults aged over fifty: an economic evaluation of the Active Plus intervention. Int J Behav Nutr Phys Act. 2014 Sep 28;11(1):122. [Epub ahead of print] PubMed PMID: 25262435.

5: Kruger J, Brennan A, Strong M, et. al. The cost-effectiveness of a theory-based online health behaviour intervention for new university students: an economic evaluation. BMC Public Health. 2014 Sep 27;14(1):1011. [Epub ahead of print] PubMed PMID: 25262372.

6: Funk LM, Zhang JY, Drosdeck JM, et. al. Long-term cost-effectiveness of medical, endoscopic and surgical management of gastroesophageal reflux disease. Surgery. 2014 Sep 24. [Epub ahead of print] PubMed PMID: 25262216.

7: Mihalopoulos C, Chen G, Iezzi A, et. al. Assessing outcomes for cost-utility analysis in depression: comparison of five multi-attribute utility instruments with two depression-specific outcome measures. Br J Psychiatry. 2014 Sep 25. [Epub ahead of print] PubMed PMID: 25257063.

8: Chung O, Vongpatanasin W, Bonaventura K, et. al. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens. 2014 Sep 24. [Epub ahead of print] PubMed PMID: 25255395.

9: Thoma A, Kaur MN, Tsoi B, et. al. Cost-Effectiveness Analysis parallel to a Randomized Controlled Trial comparing Vertical Scar Reduction (VSR) and Inverted T-Shaped reduction (ITR) mammoplasty. Plast Reconstr Surg. 2014 Sep 24. [Epub ahead of print] PubMed PMID: 25255113.

10: Snider JT, Linthicum MT, Wu Y, et. al. Economic Burden of Community-Based Disease-Associated Malnutrition in the United States. JPEN J Parenter Enteral Nutr. 2014 Sep 23. [Epub ahead of print] PubMed PMID: 25249028.

11: Bock JA, Fairley KJ, Smith RE, et. al. Cost-Effectiveness of IL28? Genotype-Guided Protease Inhibitor Triple Therapy versus Standard of Care Treatment in Patients with Hepatitis C Genotypes 2 or 3 Infection. Public Health Genomics. 2014 Sep 18. [Epub ahead of print] PubMed PMID: 25247313.

12: Tzanetakos C, Melidonis A, Verras C, et. al. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Serv Res. 2014 Sep 22;14:419. PubMed PMID: 25245666.

13: Blommaert A, Bilcke J, Vandendijck Y, et. al. Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium. Vaccine. 2014 Sep 18. [Epub ahead of print] PubMed PMID: 25239481.

14: Negrón ME, Kaplan GG, Barkema HW, et. al. Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: An Economic Evaluation. Inflamm Bowel Dis. 2014 Sep 16. [Epub ahead of print] PubMed PMID: 25230162.

15: Janzon M, James S, Cannon CP, et. al. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart. 2014 Sep 16. [Epub ahead of print] PubMed PMID: 25227704.

16: Laramée P, Brodtkorb TH, Rahhali N, et. al. The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model. BMJ Open. 2014 Sep 16;4(9):e005376. PubMed PMID: 25227627.

17: Pandya A, Gupta A, Kamel H, et. al. Carotid Artery Stenosis: Cost-effectiveness of Assessment of Cerebrovascular Reserve to Guide Treatment of Asymptomatic Patients. Radiology. 2014 Sep 16:140501. [Epub ahead of print] PubMed PMID: 25225841.

By CEA Registry Team on 9/16/2014 1:52 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Stroupe KT, Weaver FM, Cao L, et. al. Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites. Mov Disord. 2014 Sep 15. [Epub ahead of print] PubMed PMID: 25220042.

2: Graham CN, Hechmati G, Hjelmgren J, et. al. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2014 Sep 11. [Epub ahead of print] PubMed PMID: 25219451.

3: Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat. 2014 Sep 15. [Epub ahead of print] PubMed PMID: 25219291.

4: Bertapelle MP, Vottero M, Popolo GD, et. al. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. World J Urol. 2014 Sep 14. [Epub ahead of print] PubMed PMID: 25218855.

5: Burgers LT, Nauta ST, Deckers JW, et. al. Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment? Int J Cardiol. 2014 Sep 2. [Epub ahead of print] PubMed PMID: 25217221.

6: Snooks HA, Carter B, Dale J, et. al. Support and Assessment for Fall Emergency Referrals (SAFER 1): Cluster Randomised Trial of Computerised Clinical Decision Support for Paramedics. PLoS One. 2014 Sep 12;9(9):e106436. eCollection 2014. PubMed PMID: 25216281.

7: Kiadaliri AA, Gerdtham UG, Eliasson B, et. al. Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden. Diabetes Ther. 2014 Sep 12. [Epub ahead of print] PubMed PMID: 25213800.

8: Seguí MA, Crespo C, Cortés J, et. al. Genomic profile of breast cancer: cost-effectiveness analysis from the  Spanish National Healthcare System perspective.Expert Rev Pharmacoecon Outcomes Res. 2014 Sep 12:1-11. [Epub ahead of print] PubMed PMID: 25213317.

9: Greenhalgh J, Bagust A, Boland A, et. al. Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. Pharmacoeconomics. 2014 Sep 12. [Epub ahead of print] PubMed PMID: 25213036.

10: Yu SY, Lee TJ, Jang SH, et. al. Cost-Effectiveness of Nationwide Opportunistic Screening Program for Dementia in South Korea. J Alzheimers Dis. 2014 Sep 10. [Epub ahead of print] PubMed PMID: 25208621.

11: Watanabe N, Furukawa TA, Shimodera S, et. al. Cost-effectiveness of cognitive behavioral therapy for insomnia comorbid with depression: Analysis of a randomized controlled trial. Psychiatry Clin Neurosci. 2014 Sep 10. [Epub ahead of print] PubMed PMID: 25205008.

12: Png ME, Yoong JS. Evaluating the Cost-Effectiveness of Lifestyle Modification versus Metformin Therapy for the Prevention of Diabetes in Singapore. PLoS One. 2014 Sep 9;9(9):e107225. eCollection 2014. PubMed PMID: 25203633.

13: Curl P, Vujic I, van 't Veer LJ, et. al. Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma. PLoS One. 2014 Sep 8;9(9):e107255. eCollection 2014. PubMed PMID: 25198196.

14: Rawdin AC, Duenas A, Chilcott JB. The cost-effectiveness of weight management programmes in a postnatal population. Public Health. 2014 Sep 2. [Epub ahead of print] PubMed PMID: 25192882.

15: Yamauchi H, Nakagawa C, Yamashige S, et. al. Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan. BMC Health Serv Res. 2014 Sep 5;14(1):372. PubMed PMID: 25190451.

16: Boudreau DM, Guzauskas GF, Chen E, et. al. Cost-Effectiveness of Recombinant Tissue-Type Plasminogen Activator Within 3 Hours of Acute Ischemic Stroke: Current Evidence. Stroke. 2014 Sep 4. [Epub ahead of print] PubMed PMID: 25190439.

17: Rudmik L, Soler ZM, Mace JC, et. al. Economic evaluation of endoscopic sinus surgery versus continued medical therapy for refractory chronic rhinosinusitis. Laryngoscope. 2014 Sep 3. [Epub ahead of print] PubMed PMID: 25186499.

18: Pataky R, Ismail Z, Coldman AJ, et. al. Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density. J Med Screen. 2014 Sep 3. Epub ahead of print] PubMed PMID: 25186116.

19: George BP, Venkataraman V, Dorsey ER, et. al. Impact of Alternative Medical Device Approval Processes on Costs and Health. Clin Transl Sci. 2014 Sep 3. [Epub ahead of print] PubMed PMID: 25185975.

20: Cocker F, Nicholson JM, Graves N, et. al. Depression in working adults: comparing the costs and health outcomes of working when ill. PLoS One. 2014 Sep 2;9(9):e105430. eCollection 2014. PubMed PMID: 25181469.

21: Mewes JC, Steuten LM, Duijts SF, et. al. Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients. J Cancer Surviv. 2014 Sep 2. [Epub ahead of print] PubMed PMID: 25179578.

23: Mennini FS, Russo S, Marcellusi A, et. al. Economic effects of treatment of chronic kidney disease with low-protein diet. J Ren Nutr. 2014 Sep;24(5):313-21. PubMed PMID: 25167997.

24: Jacob V, Chattopadhyay SK, Elder RW, et. al.; the Community Preventive Services Task Force. Economics of Mass Media Health Campaigns with Health-Related Product Distribution: A Community Guide Systematic Review. Am J Prev Med. 2014 Sep;47(3):348-359. Review. PubMed PMID: 25145619.

25: Goodacre S, Thokala P. Pre-hospital continuous positive aireway pressure (cpap) for acute respiratory failure: an economic analysis. Emerg Med J. 2014 Sep;31(9):780-1. PubMed PMID: 25125528.

26: Brogan AJ, Smets E, Mauskopf JA, et. al. Cost Effectiveness of Darunavir/ritonavir Combination Antiretroviral Therapy for Treatment-Naive Adults with HIV-1 Infection in Canada. Pharmacoeconomics. 2014 Sep;32(9):903-17. PubMed PMID: 24906477.

27: Gómez-Outes A, Avendaño-Solá C, Terleira-Fernández AI, et. al. Pharmacoeconomic Evaluation of Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Spain. Pharmacoeconomics. 2014 Sep;32(9):919-36. PubMed PMID: 24895235.

28: Sivakanthan S, Van Gompel JJ, Alikhani P, et. al. Surgical management of trigeminal neuralgia: use and cost-effectiveness from an analysis of the medicare claims database. Neurosurgery. 2014 Sep;75(3):220-6. PubMed PMID: 24871139.

29: Goorden M, Vlasveld MC, Anema JR, et. al. Cost-utility analysis of a collaborative care intervention for major depressive disorder in an occupational healthcare setting. J Occup Rehabil. 2014 Sep;24(3):555-62. PubMed PMID: 24085535.

By CEA Registry Team on 9/2/2014 10:30 AM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Zhu XL, Chan DT, Lau CK, et al. Cost-effectiveness of subthalmic nucleus deep brain stimulation for treatment of advanced Parkinson's disease in Hong Kong : a prospective study. World Neurosurg. 2014 Aug 28. [Epub ahead of print] PubMed PMID: 25175275.

2: Honkoop PJ, Loijmans RJ, Termeer EH, et al. Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: A cluster-randomized trial in primary care. J Allergy Clin Immunol. 2014 Aug 28. [Epub ahead of print] PubMed PMID: 25174865.

3: Manning VL, Kaambwa B, Ratcliffe J, et al. Economic evaluation of a brief Education, Self-management and Upper Limb Exercise Training in People with Rheumatoid Arthritis (EXTRA) programme: a trial-based analysis. Rheumatology (Oxford). 2014 Aug 29. [Epub ahead of print] PubMed PMID: 25173349.

4: McMillan A, Bratton DJ, Faria R, et al. Continuous positive airway pressure in older people with obstructive sleep apnoea syndrome (PREDICT): a 12-month, multicentre, randomised trial. Lancet Respir Med. 2014 Aug 26. [Epub ahead of print] PubMed PMID: 25172769.

5: Kuthubutheen J, Mittmann N, Amoodi H, et al. The effect of different utility measures on the cost-effectiveness of bilateral cochlear implantation. Laryngoscope. 2014 Aug 28. [Epub ahead of print] PubMed PMID: 25169819.

6: Wilson FA, Villarreal R, Stimpson JP, et al. Cost-Effectiveness Analysis of a Colonoscopy Screening Navigator Program Designed for Hispanic Men. J Cancer Educ. 2014 Aug 30. [Epub ahead of print] PubMed PMID: 25168070.

7: Závada J, Uher M, Sisol K, et al. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann Rheum Dis. 2014 Aug 27. [Epub ahead of print] PubMed PMID: 25165033.

8: Areia M, Dinis-Ribeiro M, Rocha Gonçalves F. Cost-Utility Analysis of Endoscopic Surveillance of Patients with Gastric Premalignant Conditions. Helicobacter. 2014 Aug 28. [Epub ahead of print] PubMed PMID: 25164596.

9: Kongnakorn T, Lanitis T, Annemans L, et al. Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium. Clin Drug Investig. 2014 Aug 28. [Epub ahead of print] PubMed PMID: 25164005.

10: Alberts SR, Yu TM, Behrens RJ, et al. Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer. Pharmacoeconomics. 2014 Aug 26. [Epub ahead of print] PubMed PMID: 25154747.

11: Aitken EL, Jackson AJ, Hameed H, et al. Cephalic arch stenosis: angioplasty to preserve a brachiocephalic fistula or new brachiobasilic fistula?: a cost-effectiveness study. Ren Fail. 2014 Aug 26:1-9.[Epub ahead of print] PubMed PMID: 25154592.

12: Brown ST, Grima DG, Sauriol L. Cost-Effectiveness of Insulin Glargine Versus Sitagliptin in Insulin-Naïve Patients With Type 2 Diabetes Mellitus. Clin Ther. 2014 Aug 20. [Epub ahead of print] PubMed PMID: 25151573.

13: Lee MY, Kang HJ, Park SY, et al. Cost-Effectiveness of Tolvaptan for Euvolemic or Hypervolemic Hyponatremia. Clin Ther. 2014 Aug 20. [Epub ahead of print] PubMed PMID: 25151571.

14: Liebl A, Seitz L, Palmer AJ. Health Economics Analysis of Insulin Aspart vs. Regular Human Insulin in Type 2 Diabetes Patients, Based on Observational Real life Evidence from General Practices in Germany. Exp Clin Endocrinol Diabetes. 2014 Aug 22. [Epub ahead of print] PubMed PMID: 25148263.

15: Patel S, Ngunjiri A, Hee SW, et al. Primum non nocere: shared informed decision making in low back pain - a pilot cluster randomised trial. BMC Musculoskelet Disord. 2014 Aug 21;15(1):282. [Epub ahead of print] PubMed PMID: 25146587.

16: Ohm L, Lundqvist A, Dickman P, et al. Real-world cost-effectiveness in chronic myeloid leukaemia: The price of success during four decades of development from non-targeted treatment to imatinib. Leuk Lymphoma. 2014 Aug 20:1-16. [Epub ahead of print] PubMed PMID: 25139694.

17: Fleeman N, Bagust A, Beale S, et al. Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. Pharmacoeconomics. 2014 Aug 20. [Epub ahead of print] PubMed PMID: 25138171.

18: Smart C, Selinger CP. The cost-effectiveness of infliximab in Crohn's disease. Expert Rev Pharmacoecon Outcomes Res. 2014 Aug 20:1-10. [Epub ahead of print] PubMed PMID: 25138162.

19: Ahern CH, Shih YC, Dong W, et al. Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk. Br J Cancer. 2014 Aug 19. [Epub ahead of print] PubMed PMID: 25137022.

20: Verhaeghe N, De Smedt D, De Maeseneer J, et al. Cost-effectiveness of health promotion targeting physical activity and healthy eating in mental health care. BMC Public Health. 2014 Aug 18;14(1):856. PubMed PMID: 25134636.

21: van Hees F, Zauber AG, Klabunde CN, et al. The Appropriateness of More Intensive Colonoscopy Screening Than Recommended in Medicare Beneficiaries: A Modeling Study. JAMA Intern Med. 2014 Aug 18. [Epub ahead of print] PubMed PMID: 25133641.

By CEA Registry Team on 7/17/2014 2:43 PM

By Cayla Saret, B.A.

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Michaelidis CI, Zimmerman RK, Nowalk MP, et al. Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States. BMC Public Health. 2014 Jul 15;14(1):718. [Epub ahead of print] PubMed PMID: 25023889.

2: Amin NP, Sher DJ, Konski AA. Systematic Review of the Cost Effectiveness of Radiation Therapy for Prostate Cancer from 2003 to 2013. Appl Health Econ Health Policy. 2014 Jul 15. [Epub ahead of print] PubMed PMID: 25022451.

3: Richardson ML, Sokol ER. A cost effectiveness analysis of conservative versus surgical management for the initial treatment of stress urinary incontinence. Am J Obstet Gynecol. 2014 Jul 11. [Epub ahead of print] PubMed PMID: 25019485.

4: Treharne C, Liu FX, Arici M, et al. Peritoneal Dialysis and In-Centre Haemodialysis: A Cost-Utility Analysis from a UK Payer Perspective. Appl Health Econ Health Policy. 2014 Jul 14. [Epub ahead of print] PubMed PMID:25017433.

5: Goehler A, McMahon PM, Lumish HS, et al. Cost-Effectiveness of Follow-Up of Pulmonary Nodules Incidentally Detected on Cardiac CT Angiography in Patients with Suspected Coronary Artery Disease. Circulation. 2014 Jul 11. [Epub ahead of print] PubMed PMID: 25015342.

6: Witjes JA, Babjuk M, Gontero P, et al. Clinical and Cost Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated Expert Recommendations. Eur Urol. 2014 Jul 4. [Epub ahead of print] Review. PubMed PMID:25001887.

7: Owoicho Adogwa M, Parker SL, Shau D, et al. Cost per Quality Adjusted Life Year Gained of Revision Fusion for Lumbar Pseudoarthrosis: Defining the Value of Surgery. J Spinal Disord Tech. 2014 Jul 3. [Epub ahead of print] PubMed PMID: 24999554.

8: Ryabov I. Cost-effectiveness of Community Health Workers in controlling diabetes epidemic on the U.S.-Mexico border. Public Health. 2014 Jul 3. [Epub ahead of print] PubMed PMID: 24999158.

9: Stevenson SM, Danzig MR, Ghandour RA, et al. Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer. Urol Oncol. 2014 Jul 3. [Epub ahead of print] PubMed PMID: 24998787.

10: Levy AN, García AR, García-Agua NS, et al. Cost-effectiveness of omalizumab in severe persistent asthma in spain: a real-life perspective. J Asthma. 2014 Jul 4:1-26. [Epub ahead of print] PubMed PMID: 24995661.

11: Hulme C, Yu G, Browne C, et al. Cost-effectiveness of silicone and alginate impressions for complete dentures. J Dent. 2014 Jul 1. [Epub ahead of print] PubMed PMID: 24995472.

12: Lee D, Wilson K, Akehurst R, et al; for the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Study. Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. Heart. 2014 Jul 3. [Epub ahead of print] PubMed PMID: 24993605.

13: Coyle D, Cheung MC, Evans GA. Opportunity Cost of Funding Drugs for Rare Diseases: The Cost-Effectiveness of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. Med Decis Making. 2014 Jul 2. [Epub ahead of print] PubMed PMID: 24990825.

14: Govers T, Patel S, Takes R, et al. Cost-effectiveness of selective neck dissection versus modified radical neck dissection for treating metastases in oral cavity cancer patients; a modelling study. Head Neck. 2014 Jul 3. [Epub ahead of print] PubMed PMID: 24990207.

15: Finkelstein EA, Kruger E, Karnawat S. Cost-Effectiveness Analysis of Qsymia for Weight Loss. Pharmacoeconomics. 2014 Jul 2. [Epub ahead of print] PubMed PMID: 24986038.

16: Tran DA, Wilson DP, Shakeshaft A, et al. Cost-effectiveness of antiretroviral therapy expansion strategies in Vietnam. AIDS Patient Care STDS. 2014 Jul;28(7):365-71. PubMed PMID: 24983389.

17: Villa G, Hernández-Pastor LJ, Guix M, et al. Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain. Clin Transl Oncol. 2014 Jul 1. [Epub ahead of print] PubMed PMID: 24981588.

18: Ghogawala Z, Whitmore RG, Watters WC 3rd, et al. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 3: Assessment of economic outcome. J Neurosurg Spine. 2014 Jul;21(1):14-22. PubMed PMID: 24980580.

19: Vegter S, Oosterhof P, van Boven JF, et al. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis. J Manag Care Pharm. 2014 Jul;20(7):722-32. PubMed PMID: 24967525.

20: Webber-Foster R, Kvizhinadze G, Rivalland G, et al. Cost-effectiveness analysis of docetaxel versus weekly Paclitaxel in adjuvant treatment of regional breast cancer in new zealand. Pharmacoeconomics. 2014 Jul;32(7):707-24. PubMed PMID: 24859241.

21: Diel R, Lampenius N. Cost-Effectiveness Analysis of Interventions for Tuberculosis Control: DALYs Versus QALYs. Pharmacoeconomics. 2014 Jul;32(7):617-26. PubMed PMID: 24849396.

22: Lundberg J, Höglund M, Björkholm M, et al. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in sweden. Clin Drug Investig. 2014 Jul;34(7):483-9. PubMed PMID: 24820968.

23: Solomon DH, Patrick AR, Schousboe J, et al. The Potential Economic Benefits of Improved Postfracture Care: A Cost-Effectiveness Analysis of a Fracture Liaison Service in the US Health-Care System. J Bone Miner Res. 2014 Jul;29(7):1667-74. PubMed PMID: 24443384.

24: Sheckter CC, Van Vliet MM, Krishnan NM, et al. Cost-effectiveness comparison between topical silver sulfadiazine and enclosed silver dressing for partial-thickness burn treatment. J Burn Care Res. 2014 Jul-Aug;35(4):284-90. PubMed PMID: 24121806.

25: Raymakers AJ, Mayo J, Marra CA, et al. Diagnostic Strategies Incorporating Computed Tomography Angiography for Pulmonary Embolism: A Systematic Review of Cost-effectiveness Analyses. J Thorac Imaging. 2014 Jul;29(4):209-16. PubMed PMID: 23846107.

By CEA Registry Team on 7/16/2014 9:41 AM

By James Chambers, Ph.D. and Cayla Saret, B.A.

To date, there are few studies that examine the overall returns of medical research. A June 2014 paper in BMC Medicine quantified the returns of public and charitable funded cancer research in the UK. Matthew Glover et. al. estimated the benefits of a defined set of cancer-related interventions from 1991-2010. Interventions included prevention, screening, and treatment. In the base case, authors estimated a “substantial” 10.1% internal rate of return (IRR) for these research funds.

Interestingly, a previous work by Litchenberg that investigated the relationship among new cancer-related pharmaceuticals, pharmaceutical costs, and life year gains stated, “Ideally, we would have measured the effects of new cancer drugs on the number of quality adjusted life years (QALYS), but were unable to do so due to lack of data.(1) In their calculations, Glover et. al. used expected QALY gains, valued at £25,000/QALY,(2) to estimate the monetary benefit of improved health outcomes. Doing so allowed the authors to account for improvements not only in life expectancy, but also in quality of life. The greatest proportion of QALY gains derived from reduction in smoking (51%), followed by cervical cancer screening (21%) and breast cancer screening (19%). Interventions related to breast and prostate cancer comprised a large percentage of total net costs.

In this work, the authors seek to further validate a methodology that they used in a 2008 report to examine the returns of research related to cardiovascular disease, in which they found a similar estimated IRR of 9%. The authors do note several important limitations. For example, because only a defined set of interventions for certain cancers were included in the study, all other interventions are assumed to have zero net monetary benefit. However, the true value of excluded interventions may be positive, negative, or zero.

Dr. Jonathan Grant, who led the study by Glover et. al., said in a press release, “This return of 40 pence a year for each pound invested in cancer research includes health benefits equivalent to around 10 pence, plus a further 30 pence, which is the best estimate of the ‘spillover’ effect from research to the wider economy.  An internal rate of return of 40p easily meets the UK Government’s minimum threshold of 3.5 pence per pound for investments, showing that money spent on cancer research is good for the society as a whole, as well as benefitting patients."

 
References

     1.     Litchenberg FR: The expanding pharmaceutical arsenal in the war on cancer. NBER Working Paper Series 2004. Paper No. w10328

     2.     The midpoint of the commonly used National Institute for Health and Care Excellence values of £20,000/QALY and £30,000/QALY

By CEA Registry Team on 3/27/2014 10:26 AM

By Teja Thorat, M.Sc., M.P.H, Peter Neumann, Sc.D., and Joshua T. Cohen, Ph.D.

When we recently updated the CEA Registry for 2012, it became apparent that there was a notable spike in the number of studies added that year. Roughly 45 percent more cost-utility analyses (CUAs) were published in PubMed in 2012 than 2011 (538 versus 372).



We have identified two potential explanations for the increase:

•    Journals that have published CUAs in the past, such as the Journal of Medical Economics, PLoS ONE, Clinical Therapeutics, Pharmacoeconomics, BMJ Open, International Journal of Technology Assessment in Health Care have increased the number of CUAs they are publishing. Between 2011 and 2012, these journals have more than doubled the number of CUAs they published.

•    There was a rise in the number of journals publishing CUAs for the first time in 2012, reflecting a growing interest in the field. The Registry included 60 journals that were first-time publishers of CUAs during 2012, such as Acta Ophthalmologica, Bulletin of the World Health Organization, Journal of the American Medical Informatics Association, Journal of Cancer, Clinical Rheumatology. These include existing journals that have started publishing CUAs, or brand-new journals, or journals newly indexed on PubMed. 

Journals

Number of CUAs

2012

2011

Change from previous year

Journal of Medical Economics

38

11

27

PLoS One

21

11

10

Clinical Therapeutics

15

7

8

Pharmacoeconomics

14

7

7

BMJ Open

8

2

6

International Journal of Technology Assessment in Health Care

9

4

5

Osteoporosis International

6

1

5

Heart

6

1

5

Applied Health Economics and Health Policy

7

3

4

BMC Health Services Research

7

3

4

Breast Cancer Research and Treatment

5

1

4

European Heart Journal

4

0

4

AIDS and Behavior

4

0

4

 

Our initial count of articles published in 2013 suggests that the number of CUAs published in 2013 will be comparable to the number published in 2012. As seen in recent years, we can also expect more CUAs from emerging market countries, such as China, Japan and South Korea. For example, the number of CUAs from China increased from 3 in 2011 to 10 in 2012.  

Although we still do not understand why there has been a dramatic increase in the publication of CUAs, it is possible that it reflects an increased interest in assessing economic value, a sense that cost-utility analysis is an effective way to address this issue and to communicate findings, or some combination of the two.

 

By CEA Registry Team on 2/27/2014 9:43 AM

By Cayla Saret, BA

In a commentary published online recently in Genetics in Medicine, Scott Grosse, a health economist at the CDC’s National Center on Birth Defects and Developmental Disabilities, suggests that researchers wait to conduct cost-utility analyses (CUAs) of personalized medicine tests until evidence of their clinical utility is more thoroughly validated.(1)

Grosse worries that in the relatively new field of personalized medicine tests, cost-effectiveness studies based on early evaluations of their clinical utility may later prove unreliable.

His comments come in response to the first review, also appearing in Genetics in Medicine, to evaluate the economic value of personalized medicine tests. This research, led by Kathryn Phillips of the University of San Francisco, examined 59 CUAs published between 1998 and 2011.(2) These studies were included in the Tufts Medical Center Cost-Effectiveness Analysis Registry, a database of CUAs of health interventions.

The analysis suggests that many personalized medicine tests are relatively cost-effective. It also found that 20 percent of genetic tests saved money. However, as Grosse points out, Phillips and colleagues were careful not to draw conclusions about the cost effectiveness of genetic tests in personalized medicine as a whole.

Grosse cautions against making generalizations about the cost effectiveness of genetic tests before there is strong medical evidence of their effectiveness in improving patient outcomes. For example, he is concerned that a CUA might help decide whether to invest time and resources in a test for a cancer mutation, even though the CUA was carried out using weak evidence about the test’s clinical value. 

Phillips and her research team acknowledged that many genetic tests lack firm evidence of their clinical value. They observe, however, that often by the time this information is available, payers may have already decided whether to adopt or reject the test. So an assessment of benefits, risks, and costs is valuable in part because it occurs early in the process.

“We constantly grapple with the uncertain nature of evidence surrounding these and other new technologies,” says study co-author Peter Neumann, director of the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center. “However, decisions about new technologies, such as personalized medicine testing, need to be made on an ongoing basis.  CUAs can help inform those decisions, though we need to do a better job of understanding and characterizing the uncertainty.”

As Grosse highlights, there is value in waiting for more evidence. But constructing too high a bar for it also has consequences. Ultimately, there is a need to weigh the costs and benefits of acquiring additional information. 


References

    1.     Grosse SD. Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility. Genet Med e-pub ahead of print  14 Nov 2013.
    2.     Phillips KA, Sakowski JA, Trosman J, Douglas MP, Liang SY, Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med e-pub ahead of print  14 Nov 2013.


 

By CEA Registry Team on 1/3/2012 12:20 PM

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1. Richardson SS, Berven S. The development of a model for translation of the Neck Disability Index to utility scores for cost-utility analysis in cervical disorders. Spine J. 2011 Dec 29. [Epub ahead of print] PubMed PMID: 22209244.

2. Bouvy JC, Koopmanschap MA, Shah RR, et al. The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies. Clin Pharmacol Ther. 2011 Dec 28. doi: 10.1038/clpt.2011.224. [Epub ahead of print] PubMed PMID: 22205197.

3. Brydak L, Roiz J, Faivre P, et al. Implementing an Influenza Vaccination Programme for Adults Aged ≥65 Years in Poland: A Cost-Effectiveness Analysis. Clin Drug Investig. 2011 Dec 27. [Epub ahead of print] PubMed PMID: 22201294.

4. Montero AJ, Avancha K, Glück S, et al. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat. 2011 Dec 27. [Epub ahead of print] PubMed PMID: 22200867.

5. Anokye NK, Trueman P, Green C, Pavey TG, Hillsdon M, Taylor RS. The cost-effectiveness of exercise referral schemes. BMC Public Health. 2011 Dec 26;11(1):954. [Epub ahead of print] PubMed PMID: 22200193.

6. Wilson RD, Howe EC. A Cost-Effectiveness Analysis of Screening Methods for Dysphagia After Stroke. PM R. 2011 Dec 23. [Epub ahead of print] PubMed PMID: 22197380.

7. van Gils PF, Over EA, Hamberg-van Reenen HH, et al. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open. 2011 Dec 21;1(2):e000363. Print 2011. PubMed PMID: 22189351.

8. Gandjour A. Presenting Germany's drug pricing rule as a cost-per-QALY rule. Health Care Manag Sci. 2011 Dec 21. [Epub ahead of print] PubMed PMID: 22187356.

9. Holmes M, Carroll C, Papaioannou D. Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery: A NICE Single Technology Appraisal. Pharmacoeconomics. 2011 Dec 20. [Epub ahead of print] PubMed PMID: 22185183.

10. Cuthbertson BH, Campbell MK, Stott SA, et al. A pragmatic multi-centre randomised controlled trial of fluid loading in high-risk surgical patients undergoing major elective surgery - the FOCCUS study. Crit Care. 2011 Dec 16;15(6):R296. [Epub ahead of print] PubMed PMID: 22177541.

11. Naci H, de Lissovoy G, Hollenbeak C, et al. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents  versus routine blood transfusions: a retrospective cost-effectiveness analysis. J Med Econ. 2011 Dec 16. [Epub ahead of print] PubMed PMID: 22115328.

By James D. Chambers

By CEA Registry Team on 12/16/2011 7:35 PM

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1: Kim S, Mortaz Hedjri S, Coyte PC, et al. Cost-utility of lumbar decompression with or without fusion for patients with symptomatic degenerative lumbar spondylolisthesis. Spine J. 2011 Dec 9. [Epub ahead of print] PubMed PMID: 22169001.

2: Soini E, Hallinen T, Puolakka K, et al. Cost-effectiveness of adalimumab, etanercept and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ. 2011 Dec 14. [Epub ahead of  print] PubMed PMID: 22168785.

3: Kondo M, Yamagata K, Hoshi SL, Saito C, Asahi K, Moriyama T, Tsuruya K, Yoshida H, Iseki K, Watanabe T. Cost-effectiveness of chronic kidney disease mass screening test in Japan.  Clin Exp Nephrol. 2011 Dec 14. [Epub ahead of print] PubMed PMID: 22167460.

4: Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS One. 2011;6(12):e26783.  Epub 2011 Dec 2. PubMed PMID: 22164204; PubMed Central PMCID: PMC3229483.

5: Nosyk B, Sharif B, Sun H, Cooper C, Anis AH; on behalf of the CIHR Canadian HIV Trials Network Influenza Vaccine Research Group. The Cost-Effectiveness and Value of Information of Three Influenza Vaccination Dosing Strategies for Individuals with Human  mmunodeficiency Virus. PLoS One. 2011;6(12):e27059. Epub PMID: 22162988

6: Palmer AJ, Tucker DM. Cost and clinical implications of diabetes prevention in an Australian setting: A long-term modeling analysis. Prim Care Diabetes. 2011 Dec 6. [Epub ahead of print] PubMed PMID: 22153888.

7: Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value  Health. 2011 Dec;14(8):1068-77. PubMed PMID: 22152176.

8: Hoyle M, Rogers G, Moxham T, Liu Z, Stein K. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health. 2011 Dec;14(8):1057-67. PMID: 22152175.

9: Simpson KN, Baran RW, Kirbach SE, et al. Economics of Switching to Second-Line Antiretroviral Therapy with Lopinavir/Ritonavir in Africa: Estimates  Based on DART Trial Results and Costs for Uganda and Kenya. Value Health. 2011 Dec;14(8):1048-54. PMID: 22152173.

10: Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, et al. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health. 2011 Dec;14(8):1039-47. PMID: 22152172.

11: Fang C, Otero HJ, Greenberg D, et al. Cost-utility analyses of diagnostic laboratory tests: a systematic review. Value Health. 2011 Dec;14(8):1010-8. PMID: 22152169.

12: Park H, Rascati KL, Keith MS, et al. Cost-Effectiveness of Lanthanum Carbonate versus Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease: A US Payer Perspective. Value Health. 2011 Dec;14(8):1002-9. PMID: 22152168.

13: Thongprasert S, Permsuwan U, Ruengorn C, et al.  Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer. Asia Pac J Clin Oncol. 2011 Dec;7(4):369-75. PMID: 22151987.

14: Nayak S, Roberts MS, Greenspan SL. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med. 2011 Dec 6;155(11):751-61. PMID: 22147714.

15: Galper BZ, Moran A, Coxson PG, et al. Using Stress Testing to Guide Primary Prevention of Coronary Heart Disease among Intermediate-Risk Patients: A Cost-effectiveness Analysis. Circulation. 2011 Dec 5. [Epub ahead of print] PMID: 22144567.

16: Squires H, Simpson E, Meng Y, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess. 2011 Dec;15(40):1-210. PMID: 22142554.

17: Lee K, Chow P, Wu D, et al. An Economic Analysis between Entecavir and  Lamivudine for the Treatment of Chronic Hepatitis B in Hong Kong. J Gastroenterol Hepatol. 2011 Dec 6. [Epub ahead of print] PMID: 22141402.

18: Hall PS, McCabe C, Stein RC, Cameron D. Economic Evaluation of Genomic Test-Directed Chemotherapy for Early-Stage Lymph Node-Positive Breast Cancer. J Natl Cancer Inst. 2011 Dec 2. [Epub ahead of print] PMID: 22138097.

19: Postmus D, Abdul Pari AA, Jaarsma T, et al. A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure. Am Heart J. 2011 Dec;162(6):1096-104. PMID: 22137084.

20: Wang TS, Cheung K, Farrokhyar F, et al. Would scan, but which scan? A cost-utility analysis to optimize preoperative imaging for primary hyperparathyroidism. Surgery. 2011 Dec;150(6):1286-94. PMID: 22136852.

21: McKenna C, Maund E, Sarowar M, et al. Dronedarone for the Treatment of Atrial Fibrillation: A NICE Single Technology Appraisal. Pharmacoeconomics. 2011 Dec 2. [Epub ahead of print] PMID: 22136303.

22: McGarry LJ, Pawar VS, Parekh HH, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2011 Dec 2. [Epub ahead of print] PMID: 22135116.

23: Calvo Aller E, Maroto P, Kreif N, et al. Cost-effectiveness evaluation of sunitinib  as first-line targeted therapy for metastatic renal cell carcinoma in Spain. Clin Transl Oncol. 2011 Dec;13(12):869-77. PMID: 22126730.

24: Shauver MJ, Clapham PJ, Chung KC. An economic analysis of outcomes and complications of treating distal radius fractures in the elderly. J Hand Surg Am. 2011 Dec;36(12):1912-1918.e3. PMID: 22123045.

25: Joshi JK, Ouyang B, Prabhakaran S. Should TIA patients be hospitalized or referred to a same-day clinic?: A decision analysis. Neurology. 2011 Dec 13;77(24):2082-8. PMID: 22094477.

26: Baker TM, Goh Jo W, Johnston A, Falvey H, et al. Cost-effectiveness analysis of valsartan versus losartan and the effect of switching. J Med Econ. 2011 Dec 5. [Epub ahead of print] PMID: 22084957.

27: Carlos F, Ramírez-Gámez J, Dueñas H, et al. Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico. J Med Econ. 2011 Dec 5. [Epub ahead of print] PMID: 22082033.

28: Dakin H, Sherman M, Fung S, Fidler C, Bentley A. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a canadian public payer perspective. Pharmacoeconomics. 2011 Dec 1;29(12):1075-91. PMID: 22077579.

29: Díez-Domingo J, Ridao-López M, Gutiérrez-Gimeno MV, et al. Pharmacoeconomic assessment of implementing  a universal PCV-13 vaccination programme in the Valencian public health system (Spain). Vaccine. 2011 Dec 6;29(52):9640-8. PMID:22027484.

30: Lock K, Wilson K, Murphy D, et al. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2011 Dec;12(17):2613-26 PMID: 22017336.

31: Cahill AG, Odibo AO, Stout MJ, et al. Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis. Am J Obstet Gynecol. 2011 Dec;205(6):542.e1-7. PMID: 22000669.

32: Straub N, Grunert P, von Kries R, et al. Health economic potential of early nutrition programming: a model calculation of long-term reduction in blood  pressure and related morbidity costs by use of long-chain polyunsaturated fatty acid-supplemented formula. Am J Clin Nutr. 2011 Dec;94(6):2030S-5S. PMID: 21974892.

33: Dickson R, Bagust A, Boland A, et al. Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy: A NICE Single Technology Appraisal. Pharmacoeconomics. 2011 Dec 1;29(12):1051-62. PMID: 21967156.

34: Ekers D, Godfrey C, Gilbody S, et al. Cost utility of behavioural activation delivered by the non-specialist. Br J Psychiatry. 2011 Dec;199:510-1.  PMID: 21947655.

35: Fritzell P, Ohlin A, Borgström F. Cost-Effectiveness of Balloon Kyphoplasty Versus Standard Medical Treatment in Patients With Osteoporotic Vertebral Compression Fracture: A Swedish Multicenter Randomized Controlled Trial With 2-Year Follow-up. Spine (Phila Pa 1976). 2011 Dec 15;36(26):2243-51. PMID: 21912321.

36: Sud S, Mittmann N, Cook DJ, et al. Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation. Am J Respir Crit Care Med. 2011 Dec 1;184(11):1289-98.  PMID: 21868500.

37: Tran-Duy A, Boonen A, van de Laar MA, et al. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis. Ann Rheum Dis. 2011 Dec;70(12):2111-8.  PMID: 21857027.

38: Kowada A. Cost-effectiveness of interferon-γ release assay versus chest X-ray for tuberculosis screening of employees. Am J Infect Control. 2011 Dec;39(10):e67-72.  PMID: 21839543.

39: Tsuchiya T, Fukuda T, Furuiye M, et al. Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer. Lung Cancer. 2011 Dec;74(3):521-8. PMID: 21570734.

40: Botteman MF, Meijboom M, Foley I, et al. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. Eur J Health Econ. 2011 Dec;12(6):575-88. PMID: 20809091.

By James D. Chambers

By CEA Registry Team on 10/17/2011 8:53 AM

Twice each month we highlight recently published cost-utility studies and selected reviews and editorials.

1. Waaler Bjørnelv GM, Frihagen F, Madsen JE, et al. Hemiarthroplasty compared to internal fixation with percutaneous cannulated screws as treatment of displaced femoral neck fractures in the elderly: cost-utility analysis performed alongside a randomized, controlled trial. Osteoporos Int. 2011 Oct 14. [Epub ahead of print] PubMed PMID: 21997224.

2. Raman V, McWilliams ET, Holmberg SR, et al. Economic analysis of the use of coronary calcium scoring as an alternative to stress ECG in the non-invasive diagnosis of coronary artery disease. Eur Radiol. 2011 Oct 13. [Epub ahead of print] PubMed PMID: 21993982.

3. Wu B, Chen H, Shen J, Ye M. Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China. Clin Ther. 2011 Oct 11. [Epub ahead of print] PubMed PMID: 21992806.

4. Sun SX, Marynchenko M, Banerjee R, et al. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J Med Econ. 2011 Oct 12. [Epub ahead of print] PubMed PMID: 21992217.

5. Conly J, Clement F, Tonelli M, et al. Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. CMAJ. 2011 Oct 11. [Epub ahead of print] PubMed PMID: 21989469.

6. Gidwani R, Pashos CL, Khan ZM, et al. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes. J Med Econ. 2011 Oct 11. [Epub ahead of print] PubMed PMID: 21988635.

7. van Kempen BJ, Spronk S, Koller MT, et al. Comparative effectiveness and cost-effectiveness of computed tomography screening for coronary artery calcium in asymptomatic individuals. J Am Coll Cardiol. 2011 Oct 11;58(16):1690-701. PubMed PMID: 21982314.

8. Chen NC, Shauver MJ, Chung KC. Cost-Effectiveness of Open Partial Fasciectomy, Needle Aponeurotomy, and Collagenase Injection for Dupuytren Contracture. J Hand Surg Am. 2011 Oct 5. [Epub ahead of print] PubMed PMID: 21981831.

9. Robotham JV, Graves N, Cookson BD, et al. Screening, isolation, and decolonisation strategies in the control of meticillin resistant Staphylococcus aureus in intensive care units: cost effectiveness evaluation. BMJ. 2011 Oct 5;343:d5694. PubMed PMID: 21980062

10. Hagenmeyer EG, Koltermann KC, Dippel FW, et al. Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review. Cost Eff Resour Alloc. 2011 Oct 6;9(1):15. [Epub ahead of print] PubMed PMID: 21978524.

11. Straub N, Grunert P, von Kries R, et al. Health economic potential of early nutrition programming: a model calculation of long-term reduction in blood pressure and related morbidity costs by use of long-chain polyunsaturated fatty acid-supplemented formula. Am J Clin Nutr. 2011 Oct 5. [Epub ahead of print] PubMed PMID: 21974892.

12. Klarenbach S, Cameron C, Singh S, et al. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately  controlled on metformin. CMAJ. 2011 Oct 3. [Epub ahead of print] PubMed PMID: 21969406.

13. Dickson R, Bagust A, Boland A, et al. Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy: A NICE Single Technology Appraisal. Pharmacoeconomics. 2011 Oct 3. [Epub ahead of print] PubMed PMID: 21967156.

14. McGuire KJ, Chacko AT, Bernstein J. Cost-effectiveness of Teaching Hospitals for the Operative Management of Hip Fractures. Orthopedics. 2011 Oct 5;34(10):e598-601. doi: 10.3928/01477447-20110826-17. PubMed PMID: 21956051.

15. Pham B, Stern A, Chen W, et al. Preventing Pressure Ulcers in Long-term Care: A Cost-effectiveness Analysis. Arch Intern Med. 2011 Oct 13. [Epub ahead of print] PubMed PMID: 21949031.

16. Monksfield P, Jowett S, Reid A, et al. Cost-effectiveness Analysis of the Bone-Anchored Hearing Device. Otol Neurotol. 2011 Oct;32(8):1192-7. PubMed PMID: 21909045.

17. Mäklin S, Malmivaara A, Linna M, et al. Cost-utility of bariatric surgery for morbid obesity in Finland. Br J Surg. 2011 Oct;98(10):1422-9. PubMed PMID: 21887777.

18. Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modeling study. Lancet. 2011 Oct 1;378(9798):1219-30. Epub 2011 Aug 23. PubMed PMID:21868086.

19. Lubowitz JH, Appleby D. Cost-effectiveness analysis of the most common orthopaedic surgery procedures: knee arthroscopy and knee anterior cruciate ligament reconstruction. Arthroscopy. 2011 Oct;27(10):1317-22. Epub 2011 Aug 19. PubMed PMID: 21855268.

20. Tilson L, Jit M, Schmitz S, et al. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine. 2011 Oct 6;29(43):7463-73. Epub 2011 Aug 5.  PubMed PMID: 21821085.

21. Giardina S, Pane B, Spinella G, et al. An economic evaluation of an abdominal aortic aneurysm screening program in Italy. J Vasc Surg. 2011 Oct;54(4):938-46. Epub 2011 Aug 6. PubMed PMID: 21820837.

22. Blank PR, Moch H, Szucs TD, et al. KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective. Clin Cancer Res. 2011 Oct 1;17(19):6338-46. Epub 2011 Aug 1. PubMed PMID:21807639.

23. Chan AL, Leung HW, Huang SF. Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: a decision-tree analysis. Clin Drug Investig. 2011 Oct 1;31(10):717-26. PubMed PMID:21744880.

24. Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in belgium. Pharmacoeconomics. 2011 Oct 1;29(10):895-911. PubMed PMID:21692551.

25. Ercolani G, Cucchetti A, Cescon M, et al. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. Eur J Cancer. 2011 Oct;47(15):2291-8. Epub 2011 Jun 7. PubMed PMID: 21652204.

26. Woodhall SC, Jit M, Soldan K, et al; on behalf of the QOLIGEN study group. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect. 2011 Oct;87(6):458-463. Epub 2011 Jun 2. PubMed PMID:21636616.

27. van den Akker ME, Arts MP, van den Hout WB, et al. Tubular Diskectomy vs Conventional Microdiskectomy for the Treatment of Lumbar Disk-Related Sciatica: Cost Utility Analysis Alongside a Double-Blind Randomized Controlled Trial. Neurosurgery. 2011 Oct;69(4):829-36. PubMed PMID: 21623248.

28. Kanis JA, Cooper C, Hiligsmann M, et al. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int. 2011 Oct;22(10):2565-73. Epub 2011 May 27. PubMed PMID: 21617992.

29. Taylor M, Leonardi-Bee J, Agboola S, et al. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation. Addiction. 2011 Oct;106(10):1819-26. Epub 2011 Jul 27. PubMed PMID: 21561499.

30. Morris S, Morris TP, McGregor AH, et al. Function after spinal treatment, exercise, and rehabilitation: cost-effectiveness analysis based on a randomized controlled trial. Spine (Phila Pa 1976). 2011 Oct 1;36(21):1807-14. PubMed PMID: 21505377.

31. Thijssen AS, Broeders IA, de Wit GA, et al. Cost-effectiveness of proton pump inhibitors versus laparoscopic Nissen fundoplication for patients with gastroesophageal reflux disease: a systematic review of the literature. Surg Endosc. 2011 Oct;25(10):3127-34. Epub 2011 Apr 13. PubMed PMID: 21487859.

32. Neovius K, Buesch K, Sandström K, et al. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden. Acta Paediatr. 2011 Oct;100(10):1306-14. Epub 2011 May 13. PubMed PMID: 21477089.

33. Bøhmer E, Kristiansen IS, Arnesen H, et al. Health and cost consequences of early versus late invasive strategy after thrombolysis for acute myocardial infarction. Eur J Cardiovasc Prev Rehabil. 2011 Oct;18(5):717-23. Epub 2011 Feb 18. PubMed PMID: 2145059

By James D. Chambers

By CEA Registry Team on 10/3/2011 7:52 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials.

1. Resch B, Sommer C, Nuijten MJ, et al. Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From Austria. Pediatr Infect Dis J. 2011 Sep 28. [Epub ahead of print] PubMed PMID: 21960187.

2. Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer. 2011 Sep 29. [Epub ahead of print] PubMed PMID: 21959871.

3. Parker SL, Adogwa O, Davis BJ, et al. Cost-utility Analysis of Minimally Invasive Versus Open Multilevel Hemilaminectomy for Lumbar Stenosis. J Spinal Disord Tech. 2011 Sep 28. [Epub ahead of print] PubMed PMID: 21959840.

4. Cooper MS, Palmer AJ, Seibel MJ. Cost-effectiveness of the Concord Minimal Trauma Fracture Liaison service, a prospective, controlled fracture prevention study. Osteoporos Int. 2011 Sep 28. [Epub ahead of print] PubMed PMID: 21953475.

5. Jit M, Chapman R, Hughes O, et al. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011 Sep 27;343:d5775. PubMed PMID: 21951758.

6. Valentine WJ, Jendle J, Saraheimo M, et al. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabet Med. 2011 Sep 27. [Epub ahead of print] PubMed PMID: 21951030.

7. Pham B, Stern A, Chen W, et al. Preventing Pressure Ulcers in Long-term Care: A Cost-effectiveness Analysis. Arch Intern Med. 2011 Sep 26. [Epub ahead of print] PubMed PMID: 21949031.

8. Retèl VP, Joore MA, van Harten WH. Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance. Breast Cancer Res Treat. 2011 Sep 24. [Epub ahead of print] PubMed PMID: 21947677.

9. Ekers D, Godfrey C, Gilbody S, et al. Cost utility of behavioural activation delivered by the non-specialist. Br J Psychiatry. 2011 Sep 22. [Epub ahead of print] PubMed PMID: 21947655.

10. Bogaards JA, Coupé VM, Meijer CJ, et al. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine. 2011 Sep 22. [Epub ahead of print] PubMed PMID: 21945961.

11. Marwick TH, Scuffham PA, Hunink MG. Selection for early surgery in asymptomatic mitral regurgitation: A Markov model. Int J Cardiol. 2011 Sep 24. [Epub ahead of print] PubMed PMID: 21945713.

12. Robberstad B, Frostad CR, Akselsen PE, et al. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine. 2011 Sep 20. [Epub ahead of print] PubMed PMID: 21945264.

13. Sadique Z, Grieve R, Harrison DA, et al. Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice? Crit Care. 2011 Sep 26;15(5):R228. [Epub ahead of print] PubMed PMID: 21943177.

14. Woods B, Paracha N, Scott DA, et al. Raltirexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. Lung Cancer. 2011 Sep 19. [Epub ahead of print] PubMed PMID: 21937141.

15. Sopina E, Ashton T. Cost-effectiveness of a cervical screening program with human papillomavirus vaccine. Int J Technol Assess Health Care. 2011 Sep 22:1-8.  [Epub ahead of print] PubMed PMID: 21936972.

16. Tran BX, Ohinmaa A, Duong AT, et al. Cost-effectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam. AIDS Care. 2011 Sep 22. [Epub ahead of print] PubMed PMID: 21936718.

17. Zhang J, Denton BT, Balasubramanian H, et al. Optimization of PSA Screening Policies: A Comparison of the Patient and Societal Perspectives. Med Decis Making. 2011 Sep 20. [Epub ahead of print] PubMed PMID: 21933990.

18. Bjerklund Johansen TE, Baker TM, et al. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial. BJU Int. 2011 Sep 20. [Epub ahead of print] PubMed PMID:21933326.

19. Cipriano LE, Levesque BG, Zaric GS, et al. Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. Inflamm Bowel Dis. 2011 Sep 16.[Epub ahead of print] PubMed PMID: 21928375.

20. Hornberger J, Reyes C, Shewade A, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Sep 19. [Epub ahead of print] PubMed PMID: 21824050.

21. Blank PR, Moch H, Szucs TD, et al. KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective. Clin Cancer Res. 2011 Sep 20. [Epub ahead of print] PubMed PMID:21807639.

By James D. Chambers

By CEA Registry Team on 9/30/2011 7:45 PM

To continue the series of blogs summarizing the 2010 cost-utility literature recently added to the CEA Registry, here we focus on the type of intervention subject to cost-effectiveness analysis.

Among the 331 cost-utility studies published in 2010, approximately 32% account for pharmaceutical interventions followed by screening interventions (12%) (Figure 1). However, despite remaining the most common type of intervention evaluated, the percentage of studies evaluating pharmaceuticals was down from over 47% in previous years (Figure 2)

Figure 1: CUAs by interventions for 2010 (n=331)

Figure 2: CUAs by interventions from 1976-2010 (n=2735)

- Teja Thorat and Peter Neumann

By CEA Registry Team on 9/26/2011 9:33 AM

We recently posted on the latest updates to the Tufts CEA Registry, including the 331 articles added in 2010. Here we provide some additional data. Figure 1 shows the journals that have contributed the most 2010 articles to the Registry. The journal with highest frequency was Pharmacoeconomics (5.1%) followed by Value in Health (4.8%), Journal of Medical Economics (3.6%), Current Medical Research & Opinion (2.7%), Vaccine (2.4%) and BMJ (2.1%). 


Figure 1: CUAs by journal for 2010 (n=331)

Figure 2 displays the journals that have contributed cost-utility articles to the Registry from 1976 through 2010 (n=2735). Pharmacoeconomics has been the most frequent contributor, followed by Value in Health, International Journal of Technology Assessment in Health Care, Current Medical Research & Opinion, and Annals of Internal Medicine.

Figure 2: CUAs by journal from 1976-2010 (n=2735)

By Teja Thorat and Peter Neumann

By CEA Registry Team on 9/16/2011 5:52 PM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials.

1: Rosas SE, Feldman HI. Synthetic Vascular Hemodialysis Access Versus Native Arteriovenous Fistula: A Cost-Utility Analysis. Ann Surg. 2011 Sep 13. [Epub ahead of print] PubMed PMID: 21918428.

2: Nelson RE, Saltzman GM, Skalabrin EJ, et al. The cost-effectiveness of telestroke in the treatment of acute ischemic stroke. Neurology. 2011 Sep 14. [Epub ahead of print] PubMed PMID: 21917781.

3: Lavelle TA, Uyeki TM, Prosser LA. Cost-Effectiveness of Oseltamivir Treatment for Children with Uncomplicated Seasonal Influenza. J Pediatr. 2011 Sep 12. [Epub ahead of print] PubMed PMID: 21917267.

4: McQueen RB, Ellis SL, Campbell JD, et al. Cost-Effectiveness of Continuous Glucose Monitoring and Intensive Insulin Therapy for Type 1 Diabetes.  Cost Eff Resour Alloc. 2011 Sep 14;9(1):13.PubMed PMID:21917132.

5: Viney R, Norman R, King MT, et al. Time Trade-Off Derived EQ-5D Weights for Australia. Value Health. 2011 Sep-Oct;14(6):928-36. PubMed PMID: 21914515.

6: Vegter S, Tolley K, Keith MS, et al. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. Value Health. 2011 Sep-Oct;14(6):852-8. Epub 2011 Jun 23. PubMed PMID: 21914505.

7: Casciano R, Chulikavit M, Di Lorenzo G, et al. Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib. Value Health. 2011 Sep-Oct;14(6):846-51.. PubMed PMID: 21914504.

8: Goulart B, Ramsey S. A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer. Value Health. 2011 Sep-Oct;14(6):836-45. Epub 2011 Jun 24. PubMed PMID: 21914503.

9: Clements KM, Chancellor J, Nichol K, et al. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. Value Health. 2011 Sep-Oct;14(6):800-11. PubMed PMID: 21914499.

10: Epstein D, Sutton A. Modelling correlated clinical outcomes in health technology appraisal. Value Health. 2011 Sep-Oct;14(6):793-9. Epub 2011 Jun 25. PubMed PMID: 21914498.

11: Fritzell P, Ohlin A, Borgström F. Cost-Effectiveness of Balloon Kyphoplasty (BKP) vs. Standard Medical Treatment in Patients with Osteoporotic Vertebral Compression Fracture - a Swedish Multicenter RCT with Two Year FU. Spine (Phila Pa 1976). 2011 Sep 8. [Epub ahead of print] PubMed PMID: 21912321.

12: Ananthakrishnan AN, Hur C, Korzenik JR. Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis. Dig Dis Sci. 2011 Sep 11. [Epub ahead of print] PubMed PMID: 21909990.

13: Lyth J, Andersson SO, Andrén O, et al. A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer. Scand J Urol Nephrol. 2011 Sep 12. [Epub ahead of print] PubMed PMID: 21905981.

14: Doherty GA, Miksad RA, Cheifetz AS, et al. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. Inflamm Bowel Dis. 2011 Sep 8. doi: 10.1002/ibd.21904. [Epub ahead of print] PubMed PMID: 21905173.

15: Ternent L, Vale L, Boachie C, et al; for the Full-Thickness Macular Hole and Internal Limiting Membrane Peeling Study (FILMS) Group. Cost-effectiveness of internal limiting membrane peeling versus no peeling for patients with an idiopathic full-thickness macular hole: results from a randomised controlled trial. Br J Ophthalmol. 2011 Sep 6. [Epub ahead of print] PubMed PMID: 21900224.

16: Martin NK, Vickerman P, Miners A, et al. The cost-effectiveness of HCV antiviral treatment for injecting drug user populations. Hepatology. 2011 Sep 2. [Epub ahead of  print] PubMed PMID: 21898506.

17: Möller J, Nicklasson L, Murthy A. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. J Med Econ. 2011 Sep 5. [Epub ahead of print] PubMed PMID: 21892856.

18: McMahon PM, Kong CY, Bouzan C, et al. Cost-Effectiveness of Computed Tomography Screening for Lung Cancer in the United States. J Thorac Oncol. 2011 Sep 1. [Epub ahead of print] PubMed PMID: 21892105.

19: Greenhalgh J, Bagust A, Boland A, et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technol Assess. 2011 Sep;15(31):1-178. PubMed PMID: 21888837.

20: Bojke L, Epstein D, Craig D, et al. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis.  Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv39-iv47. PubMed PMID: 21859705.

21: Kattan MW, Earnshaw SR, McDade CL, et al. Cost Effectiveness of Chemoprevention for Prostate Cancer with Dutasteride in a High-Risk Population Based on Results from the REDUCE Clinical Trial. Appl Health Econ Health Policy.  2011 Sep 1;9(5):305-15. PubMed PMID:21875161.

22: Samuel S, Peskin B, Arondekar B, et al. Estimating health and economic benefits from using prescription omega-3 Fatty acids in patients with severe hypertriglyceridemia. Am J Cardiol. 2011 Sep 1;108(5):691-7. PubMed PMID: 21840433.

23: Praditsitthikorn N, Teerawattananon Y, Tantivess S, et al. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics. 2011 Sep 1;29(9):781-806. PubMed PMID: 21838332.

24: Tyo KR, Rosen MM, Zeng W, et al. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: Comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine. 2011 Sep 2;29(38):6686-94. Epub 2011 Jul 13. PubMed PMID: 21745516.

25: Gupta N, Bansal A, Wani SB, et al. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc. 2011 Sep;74(3):610-624.e2. Epub 2011 Jul 13. PubMed PMID:21741639.

26: Brown GC, Brown MM, Lieske HB, et al. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope. Ophthalmology. 2011 Sep;118(9):1834-43. Epub 2011 Jul 2. PubMed PMID: 21723614.

27: Juusola JL, Brandeau ML, Long EF, et al. The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA. AIDS. 2011 Sep 10;25(14):1779-87. PubMed PMID: 21716076.

28: Lesnock JL, Farris C, Krivak TC, et al. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol. 2011 Sep;122(3):473-8. Epub 2011 Jun 12. PubMed PMID: 21665250

29: Kasteng F, Eriksson J, Sennfält K, Lindgren P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2011 Sep;124(3):214-25. Epub 2011 May 24. PubMed PMID: 21609324.

30: Benedict A, Figlin RA, Sandström P, et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep;108(5):665-72. Epub 2011 Jan 25. PubMed PMID: 21265994.

31: Ruggeri M, Cicchetti A, Gasbarrini A. The cost-effectiveness of alternative strategies against HBV in Italy. Health Policy. 2011 Sep;102(1):72-80. Epub 2010  Oct 28. PubMed PMID: 21035229.

By James D. Chambers

By CEA Registry Team on 9/12/2011 8:35 AM

The CEA Registry is now fully updated with published cost-effectiveness articles through 2010. Data from 350 new articles were added to the Registry for 2010.

The Registry now contains the following:

•    2,735 cost-utility analyses on a wide variety of diseases and treatments
•    7,100 cost-effectiveness ratios
•    More than 10,000 utility weights

The CEA Registry has averaged roughly 350 new studies per year over the past few years, up from fewer than 100 per year prior to 2002 (Figure 1). 

Figure 1.  Growth in CUAs Over Time

Overall, researchers in the United States have contributed 43% of studies to the Registry, though the percent has declined somewhat over time (Figure 2).

Figure 2:  CUAs by country

In terms of types of interventions represented in the CEA Registry, pharmaceutical interventions account for 47% of the total, followed by surgical procedures (14%), care delivery (12%), medical procedure (12%) and screening (11.9%).  For studies published in 2010, pharmaceutical interventions account for 42% followed by screening (16%), surgical (12%), care delivery (10%) and medical procedure (10%).

The first wave of 2011 data should be available later this fall.

- Peter Neumann and Teja Thorat
 

By CEA Registry Team on 8/17/2011 9:18 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials.

1. Shearer DW, Kramer J, Bozic KJ, etal. Is Hip Arthroscopy Cost-effective for Femoroacetabular Impingement? Clin Orthop Relat Res. 2011 Aug 13. [Epub ahead of print] PMID: 21842295.

2. Wilson K, Hettle R, Marbaix S, et al. An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy. Eur J Cardiovasc Prev Rehabil. 2011 Aug 12. [Epub ahead of print] PMID: 21840967.

3. Squires H, Tappenden P, Cooper K, et al. Cost-Effectiveness of Aspirin, Celecoxib, and Calcium Chemoprevention for Colorectal Cancer. Clin Ther. 2011 Aug 11. [Epub ahead of print] PubMed PMID: 21840057.

4. Kowada A. Cost-effectiveness of interferon-γ release assay versus chest X-ray for tuberculosis screening of employees. Am J Infect Control. 2011 Aug 11. [Epub ahead of print] PubMed PMID: 21839543.

5. Parsi K, Chambers CJ, Armstrong AW. Cost-effectiveness analysis of a patient-centered care model for management of psoriasis. J Am Acad Dermatol. 2011 Aug 9. [Epub ahead of print] PMID: 21835497.

6. Holmes MW, Goodacre S, Stevenson MD, et al. The cost-effectiveness of diagnostic management strategies for adults with minor head injury. Injury. 2011 Aug 9. [Epub ahead of print] PubMed PMID: 21835403.

7. Rive B, Aarsland D, Grishchenko M, et al. Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway. Int J Geriatr Psychiatry. 2011 Aug 10. [Epub ahead of print] PMID: 21834130.

8. Brook RH. The role of physicians in controlling medical care costs and reducing waste. JAMA. 2011 Aug 10;306(6):650-1. PubMed PMID: 21828329.

9. Cotton BA, Kao LS, Kozar R, Holcomb JB. Cost-utility analysis of levetiracetam and phenytoin for posttraumatic seizure prophylaxis. J Trauma. 2011 Aug;71(2):375-9. PubMed PMID: 21825941.

10. Hornberger J, Reyes C, Shewade A, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Aug 9. [Epub ahead of print] PubMed PMID: 21824050.

11. Maniadakis N, Ekman M, Calvert MJ, et al. Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial. Europace. 2011 Aug 6. [Epub ahead of print] PubMed PMID: 21821852.

12. Tilson L, Jit M, Schmitz S, et al. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine. 2011 Aug 4. [Epub ahead of print] PubMed PMID: 21821085.

13. Giardina S, Pane B, Spinella G, et al. An economic evaluation of an abdominal aortic aneurysm screening program in Italy. J Vasc Surg. 2011 Aug 4. [Epub ahead of print] PMID: 21820837.

14. Shearer J, Green C, Counsell CE, et al. The impact of motor and non-motor symptoms on health state values in newly diagnosed idiopathic Parkinson's disease. J Neurol. 2011 Aug 5. [Epub ahead of print] PubMed PMID: 21818689.

15. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011 Aug 1. [Epub ahead of print] PubMed PMID: 21816193.

16. Blank PR, Moch H, Szucs TD, et al. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res. 2011 Aug 1. [Epub ahead of print] PubMed PMID: 21807639.

17. Pandor A, Goodacre S, Harnan S, et al. Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation. Health Technol Assess. 2011 Aug;15(27):1-283. PubMed PMID: 21806873.

18. Hakkaart-van Roijen L, Goettsch WG, Ekkebus M, et al. The cost-effectiveness of an intensive treatment protocol for severe dyslexia in children. Dyslexia. 2011 Aug;17(3):256-67. PMID:21793122.

19. Tung CE, Win SS, Lansberg MG. Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke. Stroke. 2011 Aug;42(8):2257-62. Epub 2011 Jun 30. PubMed PMID: 21719767.

20. Zendejas B, Moriarty JP, O'Byrne J, et al. Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J Clin Oncol. 2011 Aug 1;29(22):2993-3000. Epub 2011 Jun 20. PubMed PMID: 21690472.

21. Khdour MR, Agus AM, Kidney JC, et al. Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD. Int J Clin Pharm. 2011 Aug;33(4):665-73. PMID: 21643784.

22. Tosh JC, Wailoo AJ, Scott DL, et al. Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis. J Rheumatol. 2011 Aug;38(8):1593-600. Epub 2011 May 15. PMID: 21572149.

23. Adogwa O, Parker SL, et al. Cost-effectiveness of transforaminal lumbar interbody fusion for Grade I degenerative spondylolisthesis. J Neurosurg Spine. 2011 Aug;15(2):138-43. Epub 2011 May 6. PubMed PMID: 21529203.

24. Chuang LH, Soares MO, Watson JM, et al; on behalf of the VenUS III team. Economic evaluation of a randomized controlled trial of ultrasound therapy for hard-to-heal venous leg ulcers. Br J Surg. 2011 Aug;98(8):1099-1106. Epub 2011 Apr 20. PMID: 21509750.

25. Scotland G, McLernon D, Kurinczuk J, et al. Minimising twins in in vitro fertilisation: a modelling study assessing the costs, consequences and cost-utility of elective single versus double embryo transfer over a 20-year time horizon. BJOG. 2011 Aug;118(9):1073-1083. Epub 2011 Apr 8. PubMed PMID: 21477172.

26. Miller SM, Goldstein JL, Gerson LB. Cost-Effectiveness Model of Endoscopic Biopsy for Eosinophilic Esophagitis in Patients With Refractory GERD. Am J Gastroenterol. 2011 Aug;106(8):1439-45. Epub 2011 Mar 29. PubMed PMID: 21448144.

27. Noah-Vanhoucke J, Green LE, Dinh TA, et al. Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population. Cancer. 2011 Aug 1;117(15):3322-31. Epub 2011 Mar 14. PubMed PMID: 21404271.

28. Bosmans JE, Pool JJ, de Vet HC, et al. Is behavioral graded activity cost-effective in comparison with manual therapy for patients with subacute neck pain?: an economic evaluation alongside a randomized clinical  trial. Spine (Phila Pa 1976). 2011 Aug 15;36(18):E1179-86. PMID: 21343847.

29. Leong RK, de Wachter SG, Joore MA, et al. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin. A treatment for patients with idiopathic overactive bladder. BJU Int. 2011 Aug;108(4):558-64. PMID: 21166750.

By James D. Chambers

By CEA Registry Team on 8/1/2011 9:34 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials.

1. Barton P, Andronis L, Briggs A, et al. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. BMJ. 2011 Jul 28;343:d4044. PubMed PMID: 21798967.

2. Yamamoto N, Mori R, Jacklin P, et al. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis. BJOG. 2011 Jul 28. PubMed PMID: 21794070.

3. de Lima Lopes G Jr, Segel JE, Tan DS, et al. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer. 2011 Jul 26. PubMed PMID: 21792863.

4. Dy CJ, McCollister KE, Lubarsky DA, et al. An economic evaluation of a systems-based strategy to expedite surgical treatment of hip fractures. J Bone Joint Surg Am. 2011 Jul 20;93(14):1326-34. PubMed PMID: 21792499.

5. Holland DP, Sanders GD, Hamilton CD, et al. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS One. 2011;6(7):e22276. Epub 2011 Jul 18. PubMed PMID: 21789248

6. Ananthakrishnan AN, Hur C, Juillerat P, et al. Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis. Am J Gastroenterol. 2011 Jul 26. PubMed PMID: 21788991.

7. Mennini FS, Panatto D, Marcellusi A, et al. Time Trade-Off Procedure for Measuring Health Utilities Loss With Human Papillomavirus-Induced Diseases: A Multicenter, Retrospective, Observational Pilot Study in Italy. Clin Ther. 2011 Jul 23. PubMed PMID: 21788076.

8. Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study. Neurology. 2011 Jul 26;77(4):355-63. PubMed PMID: 21775734

9: Murphy JD, Chang DT, et al. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer. 2011 Jul 19. PubMed PMID: 21773972.

10. Aberg F, Mäklin S, Räsänen P, et al. Cost of a quality-adjusted life year in liver transplantation: The influence of indication and MELD score. Liver Transpl. 2011 Jul 18. PubMed PMID: 21770017.

11. Brent RJ. The effects of HIV medications on the quality of life of older adults in New York City. Health Econ. 2011 Jul 18. doi: 10.1002/hec.1774. PubMed PMID: 21766480.

12. Price D, Gray A, Gale R, et al. Cost-utility analysis of indacaterol in Germany: A once-daily maintenance bronchodilator for patients with COPD. Respir Med. 2011 Jul 15. PubMed PMID: 21764277.

13. Glazener C, Boachie C, Buckley B, et al. Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials. Lancet. 2011 Jul 23;378(9788):328-37. PubMed PMID: 21741700.

By James D. Chambers

By CEA Registry Team on 7/27/2011 2:31 PM

July 28th is World Hepatitis Day.  In recognition, we searched the CEA Registry for estimates of cost-effectiveness of hepatitis C (HCV) screening (Table 1). 

Globally, hepatitis is a hugely burdensome disease with nearly 1 in 12 people suffering from hepatitis. [1]  If left undiagnosed and untreated, hepatitis can lead to disability, liver scarring, and liver cancer. 

The results of our search show a wide range of cost-effectiveness estimates for hepatitis screening, from dominant strategies (more effective and less costly than the comparator) to those that are dominated (less effective and more costly than the comparator).  Strategies that target people with risk factors for contracting hepatitis are the most cost-effective, including strategies targeting injection drug users and the prison population. 
 

Table 1. Cost-effectiveness of hepatitis C screening in a variety of circumstances

Reference
US$/QALY
Intervention      
Comparator      Target Population               
Tramarin 2008 Curr Pharm Des (PMID 18673188) Cost-Saving HCV serology every 6 month, lifelong No screening Injected Drug Users (IDUs) in the Veneto Region, Italy
 
Pereira 2000 Transfusion (11061853) Cost-Saving Screening blood for HCV using current protocols Screening blood for HCV using surrogate markers Blood transfusion recipients
Stein 2004 J Public Health (Oxf) (15044577) 50000 Screening for HCV No Screening Patients with history of drug use
Sutton 2008 J Viral Hepat (18637074) 120000 Screening for HCV Usual care -- symptomatic testing within community Prison population of England and Wales
Stein 2003 J Hepatol (14568266) 150000 Universal screening for HCV No screening    Adult patients attending genitourinary medicine clinics in England
Leal 1999 J Med Screen (10572842) 150000 Screening for HCV    Status quo IV drug users in contact with the health care system in South and West health regions of the UK.
Plunkett 2005 Am J Obstet Gynecol (15846195) 1.40E+06 HCV screening, treatment, and elective cesarean delivery No screening Asymptomatic, HIV-negative pregnant women without risk factors for HCV infection who received routine prenatal care in the US
Pereira 2000 Transfusion (11061853) 2.40E+06 Screening HCV using RNA testing added to current protocols Screening blood for HCV using current protocols Blood transfusion recipients
Plunkett 2005 Am J Obstet Gynecol (15846195) Dominated HCV screening and treatment    No screening Asymptomatic, HIV-negative pregnant women without risk factors who received routine prenatal care in the US
Singer 2001 Am J Med (11755504) Dominated Screening for HCV No screening Asymptomatic, average risk adults (HCV)

 

These findings are consistent with those in Cohen et al 2009. [2]  In certain circumstances screening offers tremendous value, increasing health while decreasing the overall cost of care.  However, in other circumstances screening strategies can be highly cost-ineffective, resulting in little or no health gain for the investment.  While screening offers great potential to increase health and generate cost-savings, it is important to target appropriate populations (e.g., those at risk).

You can find out more information regarding hepatitis, including information on prevention, diagnosis, and treatment at: http://www.worldhepatitisalliance.org.

By: Michael J. Cangelosi and James D. Chambers

References
[1] ELPA-info.org (2010) Avilable Online at:www.elpa-info.org
[2] Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med. 2008 Feb 14;358(7):661-3

By CEA Registry Team on 7/26/2011 8:12 AM

On July 19th, the Centers for Medicare and Medicaid Services (CMS) posted two proposed decision memos pertaining to screening on their website:  screening and behavioral counseling interventions in primary care to reduce alcohol misuse; and screening for depression in adults. [1] [2]

These proposed decisions are notable in that they include discussions of cost-effectiveness.

In both cases, CMS appeals to the Medicare Improvements for Patients and Providers Act (MIPPA) of 2008 (§1861(ddd)(2)) to justify inclusion of cost-effectiveness evidence: 

“Cost and cost-effectiveness studies were also searched (as part of the internal technology assessment), as §1861(ddd)(2) expressly authorizes the agency to “conduct an assessment of the relation between predicted outcomes and the expenditures for such services”.”

In both instances, the proposed decisions are consistent with the cost-effectiveness evidence.  The proposed decision for screening and counseling to reduce alcohol misuse included review of Solberg et al, 2008. [3] This study presented an analysis that estimated the intervention to be cost-saving from the societal perspective and to have a cost-effectiveness ratio of $1755/QALY saved from a health-system perspective.

The proposed decision for screening for depression in adults presented the findings of Simon et al, 2007. [4] The results showed that compared to usual care, screening using multicomponent depression management was dominant, accumulating 61 additional depression free days while accumulating savings of $314 per patient.

Given recent health reform legislation restricting the use of cost/QALYs [5], CMS’s review of a cost-utility study (Solberg et al) may come as a surprise.  Its inclusion is further explained through the following text:

Although this evaluation regarding the cost-effectiveness of screening for alcohol misuse used quality-adjusted life years (QALYs), CMS does not have and is not establishing in this proposed decision memorandum a coverage threshold for QALYs.  See 1182(e) of the Social Security Act.

Regular readers of this blog will be aware of other recent instances of CMS reviewing cost-effectiveness evidence for preventative care (here and here).  The new decisions seem to form something of a trend for CMS including cost-effectiveness evidence in their reviews for preventative care.

As blog readers also know, the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center maintains the Tufts NCD Database that includes detailed information on all NCDs from 1999 through 2011.

By James D. Chambers

References
1. Proposed Decision Memo for Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse (CAG-00427N). Available here
2. Proposed Decision Memo for Screening for Depression in Adults (CAG-00425N). Available here
3. Solberg L, Maciosek M and Edwards N.  Primary care intervention to reduce alcohol misuse ranking its health impact and cost effectiveness.  American Journal of Preventive Medicine 2008 February;34(2):143-152
4. Simon G, Katon W, Lin E, et al.  Cost-effectiveness of systematic depression treatment among people with diabetes mellitus.  Archives of General Psychiatry 2007 Januarry;64(1):65-72
5. Chambers JD, Neumann PJ.  US healthcare reform: implications for health economics and outcomes research.  Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):215-6 Available here

 

By CEA Registry Team on 7/21/2011 7:31 AM

In a new paper, my colleagues and I review the literature on the cost-effectiveness of interventions for chronic kidney disease (CKD). [1]

We searched the Tufts Cost-Effectiveness Analysis Registry (www.cearegistry.org) and other sources and grouped the findings into three categories – stage 1–4 CKD, transplant and end-stage renal disease (ESRD). 

The results highlight the growing number of cost-effectiveness analyses available on interventions for CKD.  The study includes detail on 72 cost-utility analyses and 20 cost-effectiveness analyses (where outcomes are measured in terms of cost per life year gained). Many of the interventions identified are cost saving or cost-effective under conventional thresholds (e.g., $100,000 per QALY or life year gained). 

The study also shows the need to improve the methodological quality and usability of studies.  As we’ve noted in other research [2], there is variability in the methods used to estimate cost-effectiveness ratios.  In terms of usability, the studies identified sometimes omit important implementation barriers (e.g., limits in the number of organs for transplantation or patient education, or changes to the reimbursement system needed to encourage greater use of home hemodialysis).

Still, as CMS has moved to a bundled payment for ESRD, there will be a greater need to manage kidney disease patients efficiently.  That should mean a growing importance of cost-effectiveness analyses in the future.

By Peter J. Neumann

References
1. Menzin J, Lines LM, Weiner DE, Neumann PJ, Nichols C, Rodriquez L, Agodoa I, Mayne T.  A review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease.  Pharmacoeconomics. 2011
2. Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB.  Growth and quality of the cost-utility literature, 1976-2001. Value in Health. 2005;8(1):3–9.

By CEA Registry Team on 7/15/2011 8:42 AM

Twice each month we highlight recently published cost utility studies and selected reviews and editorials.

1. Tyo KR, Rosen M, Zeng W, et al.  Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: Comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine. 2011 Jul 8. [Epub ahead of print] PubMed PMID: 21745516.

2. Chan AL, Leung HW, Huang SF. Cost Effectiveness of Cetuximab Concurrent with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Taiwan: A Decision-Tree Analysis. Clin Drug Investig. 2011 Jul 12. [Epub ahead of print] PubMed PMID: 21744880.

3. Campbell HE, Epstein D, et al. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur  J Cancer. 2011 Jul 7. [Epub ahead of print] PubMed PMID: 21741831.

4. Glazener C, Boachie C, Buckley B, et al.  Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials. Lancet. 2011 Jul 7. [Epub ahead of print] PubMed PMID: 21741700.

5. Gupta N, Bansal A, Wani SB, et al. Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc. 2011 Jul 7. [Epub ahead of print] PubMed PMID: 21741639.

6. Sullivan SD, Garrison LP, Rinde H, Kolberg J, Moler EJ. Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score. J Med Econ. 2011 Jul 11. [Epub ahead of print] PubMed PMID: 21740291.

7. Sund B, Svensson L, Rosenqvist M, et al. Favourable cost-benefit in an early defibrillation programme using dual dispatch of ambulance and fire services in out-of-hospital cardiac arrest. Eur J Health Econ. 2011 Jul 8. [Epub ahead of  print] PubMed PMID: 21739334.

8. Kobelt G, Lekander I, Lang A, et al. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care. 2011 Jul 8:1-8. [Epub ahead of print] PubMed PMID: 21736857.

9. Colquitt J, Jones J, Harris P, et al. Bone-anchored hearing aids (BAHAs) for people who are bilaterally deaf: a systematic review and economic evaluation. Health Technol Assess. 2011 Jul;15(26):1-200. PubMed PMID: 21729632.

10. Prenzler A, Yen L, Mittendorf T, von der Schulenburg JM. Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. BMC Health Serv Res. 2011 Jul 5;11(1):157. [Epub ahead of print] PubMed PMID: 21729262.

11. Lowin J, Bergman A, Ray Chaudhuri K, et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK. J Med Econ. 2011 Jul 6. [Epub ahead of print] PubMed PMID: 21728911.

12. Schousboe JT, Kerlikowske K, Loh A, et al. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011 Jul 5;155(1):10-20. PubMed  PMID: 21727289.

13. Spronk S, van Kempen BJ, Boll AP, et al. Cost-effectiveness of screening for abdominal aortic aneurysm in the Netherlands and Norway. Br J Surg. 2011 Jul 4. doi: 10.1002/bjs.7620. [Epub ahead of print] PubMed PMID: 21725968.

14. Cummins E, Asseburg C, Prasad M, et al. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ. 2011 Jul 1. [Epub ahead of print] PubMed PMID: 21720868.

15. Davis JC, Marra CA, Robertson MC, et al. Sustained Economic Benefits of Resistance Training in Community-Dwelling Senior Women. J Am Geriatr Soc. 2011 Jul;59(7):1232-1237. Epub 2011 Jun 30. PubMed PMID: 21718265.

16. Juusola JL, Brandeau ML, Long EF, et al. The Cost-Effectiveness of Symptom-Based Testing and Routine Screening for Acute HIV Infection in Men Who Have Sex with Men in the United States. AIDS. 2011 Jul 8. [Epub ahead of print] PubMed PMID: 21716076.

17. Lazar LD, Pletcher MJ, Coxson PG, et al. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011 Jul 12;124(2):146-53. Epub 2011 Jun 27. PubMed PMID: 21709063.

18. Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart. 2011 Jul;97(14):1175-81. PubMed PMID: 21685482.

19. Mueller D, Gandjour A. Cost Effectiveness of Secondary vs Tertiary Prevention for Post-Menopausal Osteoporosis. Appl Health Econ Health Policy. 2011 Jul 1;9(4):259-73. PubMed PMID: 21682353.

20. Luangasanatip N, Chaiyakunapruk N, Upakdee N, et al. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. Clin Drug Investig. 2011 Jul 1;31(7):493-505. PubMed PMID: 21627338.

21. Szucs TD, Kressig RW, Papageorgiou M, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011 Jul 1;7(7). [Epub ahead of print] PubMed PMID: 21606685.

22. Muntinghe FL, Vegter S, Verduijn M, et al. Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients. Pharmacogenet Genomics. 2011 Jul;21(7):417-25. PubMed PMID: 21597398.

23. Schipper LG, Kievit W, den Broeder AA, et al. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford). 2011 Jul;50(7):1320-30. Epub 2011 Mar 2. PubMed PMID: 21371999.

24. Naik S, Lundberg J, Kumar R, et al. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden. Scand J Infect Dis. 2011 Jul;43(6-7):504-14. Epub 2011 Feb 18. PubMed PMID: 21332286.

25. Maes IH, Joore MA, Cima RF, et al. Assessment of Health State in Patients With Tinnitus: A Comparison of the EQ-5D and HUI Mark III. Ear  Hear. 2011 Jul-Aug;32(4):428-35. PubMed PMID: 21221004.

26. Werner EF, Han CS, Pettker CM, et al. Universal cervical-length screening to prevent preterm birth: a cost-effectiveness analysis. Ultrasound Obstet Gynecol. 2011 Jul;38(1):32-7. Epub 2011 May 24. PubMed PMID: 21157771.

27. Linde C, Mealing S, Hawkins N, et al; on behalf of the REVERSE study group. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction). Eur Heart J. 2011 Jul;32(13):1631-1639. Epub 2010 Nov 25. PubMed PMID: 21112898.

28. Fritzell P, Berg S, Borgström F, et al. Cost effectiveness of disc prosthesis versus lumbar fusion in patients with chronic low back pain: randomized controlled trial with 2-year follow-up. Eur Spine J. 2011 Jul;20(7):1001-1011. Epub 2010 Nov 5. PubMed PMID: 21053028.

29. Koffijberg H, Buskens E, Rinkel GJ. Aneurysm occlusion in elderly patients with aneurysmal subarachnoid haemorrhage: a cost-utility analysis. J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):718-27. Epub 2009 Dec 3. PubMed PMID: 19965848.

By James D. Chambers

By CEA Registry Team on 7/11/2011 10:37 AM

The CEA Registry Team is pleased to announce that the Tufts Cost-Effectiveness Registry (